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ABSTRACT 
Marissa Ann Schiel 
 
Human Carboxylesterase 2 Splice Variants:  Expression, Activity, and Role in the 
Metabolism of Irinotecan and Capecitabine 
 
Carboxylesterases (CES) are enzymes that metabolize a wide variety of 
compounds including esters, thioesters, carbamates, and amides.  In humans there are 
three known carboxylesterase genes CES1, CES2, and CES3.  Irinotecan (CPT-11) and 
capecitabine are important chemotherapeutic prodrugs that are used for the treatment of 
colorectal cancer. Of the three CES isoenzymes, CES2 has the highest catalytic efficiency 
for irinotecan activation.  There is large inter-individual variation in response to treatment 
with irinotecan.  Life-threatening late-onset diarrhea has been reported in approximately 
13% of patients receiving irinotecan.  Several studies have reported single nucleotide 
polymorphisms (SNPs) for the CES2 gene.  However, there has been no consensus on the 
effect of different CES2 SNPs and their relationship to CES2 RNA expression or 
irinotecan hydrolase activity.  Three CES2 mRNA transcripts of approximately 2kb,3kb, 
and 4kb have been identified by multi-tissue northern analysis.  The expressed sequence 
tag (EST) database indicates that CES2 undergoes several splicing events that could 
generate up to six potential proteins.  Four of the proteins CES2, CES2Δ458-473, CES2+64, 
CES2Δ1-93 were studied to characterize their expression and activity.  Multi-tissue 
northern analysis revealed that CES2+64 corresponds to the 4kb and 3kb transcripts while 
CES2Δ1-93 is located only in the 4 kb transcript.  CES2Δ458-473 is an inactive splice variant 
viii 
that accounts for approximately 6% of the CES2 transcripts in normal and tumor colon 
tissue.  There is large inter-individual variation in CES2 expression in both tumor and 
normal colon samples.  Characterization of CES2+64 identified the protein as normal 
CES2 indicating that the signal peptide is recognized in spite of the additional 64 amino 
acids at the N-terminus.  Sub-cellular localization studies revealed that CES2 and 
CES2+64 localize to the ER, and CES2Δ1-93 localizes to the cytoplasm.  To date CES2 SNP 
data has not provided any explanation for the high inter-individual variability in response 
to irinotecan treatment.  Multi-tissue northern blots indicate that CES2 is expressed in a 
tissue specific manner.  We have identified the CES2 variants which correspond to each 
mRNA transcript.  This information will be critical to defining the role of CES2 variants 
in the different tissues.   
 
William F. Bosron, Ph.D. 
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INTRODUCTION 
Carboxylesterases (CES) are enzymes that metabolize a wide variety of 
compounds including esters, thioesters, carbamates, and amides.  In humans there are 
three known carboxylesterase genes CES1, CES2, and CES3.  Of the three, CES2 has the 
highest catalytic efficiency with regards to irinotecan metabolism.  CES2 as well as CES1 
also contribute to the metabolism of capecitabine.  Both irinotecan (CPT-11) and 
capecitabine are important chemotherapeutics for the treatment of colorectal cancer.  
There is large inter-individual variation in response to treatment with irinotecan.  Life-
threatening late-onset diarrhea has been reported in about 13% of patients receiving 
irinotecan.  Several studies have reported single nucleotide polymorphisms (SNPs) for 
the CES2 gene.  However, there has been no consensus on the effect of different CES2 
SNPs and their relationship to CES2 RNA expression or irinotecan hydrolase activity.  
The expressed sequence tag (EST) database indicates that CES2 undergoes several 
splicing events that could lead to six potential proteins.  It is essential to study the 
pharmacodynamics and pharmacokinetics of these drugs in order to improve treatment 
outcomes and limit side effects.  It is our hypothesis that inter-individual variation in 
response to irinotecan and capecitabine therapy, used for the treatment of colorectal 
cancer, may be attributed to the expression levels and activities of the CES2 splice 
variants.  Only one of the six potential proteins, wild-type CES2, has been studied to a 
significant degree.  The goal of this research is to understand the expression patterns and 
activity of the CES2 splice variants and to study factors that are responsible for the inter-
individual variation in response to irinotecan and capecitabine treatment. 
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I. Carboxylesterase genes and enzyme functions 
Carboxylesterases (CES) (E.C.3.1.1.1) are α/β-hydrolase fold proteins belonging 
to the serine esterase superfamily (Aldridge, 1993).  Members of the superfamily of α/β 
hydrolases are described at the ESTHER database (Hotelier et al., 2004).  
Carboxylesterases catalyze the hydrolysis of esters, thioesters, carbamates, and amides.  
Endogenous substrates of carboxylesterases include short and long chain acyl-glycerols, 
long chain acylcarnitines, and long-chain acyl CoA esters.  A significant physiological 
role of carboxylesterases is the detoxification of exogenous compounds as well as the 
activation of prodrugs (Satoh and Hosokawa, 1998).  Catalyzing phase I hydrolysis 
reactions, carboxylesterases can increase the polarity of an exogenous substrate thus 
enhancing its elimination.  Exogenous substrates of carboxylesterases include 
angiotensin-converting enzyme inhibitors, salicylates, haloperidol, cocaine, heroin, and 
the chemotherapeutics irinotecan and capecitabine (Satoh and Hosokawa, 1998).  Due to 
their broad substrate specificity and ability to function as esterases or lipases, it became 
increasingly difficult to classify carboxylesterases by substrate type.  Satoh and 
Hosokawa (1998) proposed a novel classification system that organized the 
carboxylesterases into four main classes based on sequence similarity.  More recently a 
fifth class of carboxylesterases has been identified that differs in structure from the other 
four families (Satoh and Hosokawa, 2006).   
In humans, there are five carboxylesterase classes recognized by the Human Gene 
Organization Nomenclature Committee (Eyre et al., 2006) (Table 1)  The three major 
carboxylesterase genes CES1, CES2, and CES3 each belong to a different class (Satoh 
and Hosokawa, 1998).  CES1 is a 180kDa trimer, while CES2 and CES3 are  
3 
60kDa monomers.  There is approximately 48% sequence homology between CES1 and 
CES2.  CES3 shares approximately 40% sequence homology with both CES1A1 and 
CES2 (Sanghani et al., 2004).  CES1 is ubiquitously expressed, and CES2 is mainly 
found in the liver and intestines (Quinney et al., 2005; Satoh et al., 2002; Wu et al., 
2003).  CES3 has a similar tissue distribution pattern to that of CES2 (Sanghani et al., 
2004) (Figure 1).  However, the amount of CES3 transcript in the colon is significantly 
less than that of CES2 (Sanghani et al., 2003). 
 
 
 
HUGO 
nomenclature 
GeneID Genbank Accession 
number 
Gene Type Aliases 
CES1 1066 NM_001025195 NM_001025194 Protein coding 
hCE1, CEH, 
PCE-1 
CES2 8824 NM_003869 NM_198061 Protein coding 
hCE2, iCE, 
PCE-2 
CES3a 23491 NM_024922 Protein coding  
CES4 51716 NR_003276 Pseudo  
CES7 221223 NM_145024  Protein coding 
CAUXIN, 
CES5 
 
Table 1. Human carboxylesterase gene family  
((Sanghani et al., 2008, accepted for publication)) 
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Figure 1. Multi-tissue Northern blot analysis of human carboxylesterases:  
Distribution of carboxylesterases in human tissues was examined using a multi-tissue 
Northern Blot purchased from Origene Technolgies (Rockville, MD).  Specific cDNA 
probes were developed for CES1, CES2, and CES3.  β-actin was probed as a loading 
control.  Exposure time varied from 12 hours (CES1) to 8 days (CES3).  
(From Quinney, 2004)) 
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The majority of mammalian carboxylesterases are glycosylated ER proteins 
containing ER signal peptide and retention sequences at the N-terminus and C-terminus, 
respectively (Satoh and Hosokawa, 1998).  However, Takagi et al. (1988) and Long et al. 
(1988) have reported sequences that encode for secretory carboxylesterases.  The ER 
signal sequence generally is comprised of 17-20 hydrophobic amino acids with a bulky 
aromatic residue proceeded by a small neutral residue immediately followed by the 
cleavage site (von, 1983).  The C-terminal HXEL consensus sequence (Robbi and 
Beaufay, 1991) interacts with the KDEL receptor in the ER lumen (Satoh and Hosokawa, 
1998).  N-linked glycosylation motifs N-X-S/T-(P) are also conserved among the 
carboxylesterases.  Kroetz et al. (1993) provided data indicating that glycosylation may 
be necessary for optimal esterase activity.  Many carboxylesterases also contain four 
cysteine residues that are involved in disulfide bonds.  The carboxylesterase conserved 
catalytic site is comprised of a triad of the amino acid residues serine (Ser), glutamate 
(Glu), and histidine (His) (Cygler et al., 1993; Hosokawa, 2008; Satoh and Hosokawa, 
1998).  Carboxylesterases hydrolyze substrates by a two-step, ping-pong catalytic 
mechanism.  Histidine acts as a base to remove a proton from serine.  The serine-O- 
nucleophile is free to attack the carbonyl group of the substrate forming a tetrahedral 
intermediate.  Two conserved glycine residues form an oxyanion hole which serves to 
stabilize the tetrahedral intermediate.  The ester bond breaks and acyl-enzyme complex 
forms.  Glutamate and histidine pair within the catalytic triad to stabilize and orient the 
structure.  Histidine donates a proton to the alcohol leaving group.  A water molecule acts 
as a nucleophile and attacks the acyl-enzyme intermediate producing a second tetrahedral 
6 
intermediate.  The carboxylic acid product is eliminated, and the enzyme catalytic site is 
reconstituted.    
II. CES2 structure and polymorphisms 
Pindel et al. (1997) reported the cloning of a 533-amino acid mature human liver 
h-CE2 (old nomenclature for CES2) which displayed 73% homology to rabbit liver CES2 
and 67% homology to hamster AT51p.  CES2 is a 60kDa serine ester hydrolase 
(carboxylesterase) with Ser228, Glu345, and His457 forming its catalytic triad.  There is an 
ER signal peptide within the first 27 N-terminal amino acid residues.  The C-terminus has 
the ER retention sequence HTEL (Pindel et al., 1997; Robbi and Beaufay, 1991).  Two 
N-linked glycosylation sites are located at residues Asn111 and Asn276 (Schwer et al., 
1997). 
The CES2 gene is situated on chromosome 16, spans 10 kb, and includes 12 
exons.  Eleven splice variants encoding ten proteins are reported for CES2 in the 
AceView database (Thierry-Mieg and Thierry-Mieg, 2006).  The AceView database 
“provides a strictly cDNA-supported view of the human transcriptome and the genes by 
summarizing all quality-filtered human cDNA data from GenBank, dbEST and the 
RefSeq” (Thierry-Mieg and Thierry-Mieg, 2006).  The expressed sequence tag (EST) 
database (Unigene) indicates that CES2 includes two in-frame ATGs in exon 1 and 
potential alternative splicing sites in exon 1 and exon 10 (Figure 2).  Combinations of 
these splicing events could lead to six potential CES2 protein splice variants (Figure 3).  
Only one of the six proteins, wild-type CES2 (indicated with an arrow in Figure 3), has 
been studied to a significant degree.  It is believed that CES2 is expressed when 
translation begins at the second ATG in exon 1; it is surrounded by the Kozak consensus 
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Northern blot analysis of CES2 reveals three transcripts (Satoh et al., 2002; 
Schwer et al., 1997; Wu et al., 2003) of approximately 2 kb, 3 kb, and 4.2 kb in length.  
The expression pattern and intensity varies between the different tissue types (Figure 1).  
The 2 kb and 3 kb transcripts are largely expressed in the liver, colon, and small intestine 
and to a lesser degree in the heart. The approximately 4 kb transcript is located in the 
brain, kidney, and testes.  The multiple transcripts may arise from splice variants or the 
use of alternate promoters (Satoh et al., 2002; Wu et al., 2003).   
 
 
Figure 3. CES2 variant proteins:  Based on the splicing shown in Figure 2 there 
are six potential CES2 proteins.  The protein marked by the arrow is the most 
commonly studied isoform of CES2.  Serine (S), Glutamate (E), and Histidine (H) 
are the three catalytic site residues.  Alternative splicing in exon 10 removes the 16 
amino acid residues immediately following the catalytic residue, Histidine.  CES2 is 
a glycoprotein with the glycosylation sites marked GLY.   
9 
Seventy-two single nucleotide polymorphisms (SNPs) for CES2 have been 
identified in the NCBI SNP database.  There are seven SNPs reported in the coding 
region of which four are nonsynonymous.  Different labs have reported single nucleotide 
polymorphisms for the CES2 gene (Charasson et al., 2004; Kim et al., 2003; Kubo et al., 
2005; Marsh et al., 2004; Wu et al., 2004).  Marsh et al. (2004) found no correlation 
between SNPs and CES2 mRNA expression in normal tissues, but the intronic SNP 
IVS10-88 was associated with decreased CES2 mRNA levels in colorectal tumors.  
Studying the Japanese population, Kim et al. (2003) found no such association but did 
find R34W to have decreased enzymatic activity.  As a follow-up study, Kubo et al. 
(2005) reported that two nonsynonymous SNPs, C100T (R34W) and G424A (V124M), 
resulted in decreased carboxylesterase activity in spite of increased protein expression. 
Also, the intronic SNP IVS8-2A resulted in truncated proteins.  Charasson et al. (2004) 
did not identify any SNPs that had significant influence on mRNA expression or CES 
activity.  These studies indicate that there is confusion as to the role of SNPs in inter-
individual variation in response to irinotecan.  
 
 Nucleotide Amino acid SNP number 
1 C1406T R136ter rs28382815 
2 G1685A A229T rs11568312 
3 G1809A R270H rs8192924 
4 G1937A G313R rs10852434 
 
Table 2. Nonsynonymous coding SNPs reported for CES2:  The amino acid numbers 
include an additional 64 amino acids at the N-terminal of CES2.  Ter = termination. 
10 
III. Gene splicing 
For a gene to be expressed, the genomic code must be transcribed into RNA 
which is then translated into protein.  A key element of this process is the splicing of pre-
mRNA into mature mRNA.  Splicing is the process whereby non-coding intronic 
sequences are removed from the pre-mRNA and the exons are re-ligated to form the 
mature mRNA molecule (Nilsen, 2003).  On average greater than 90% of pre-mRNA 
sequence is spliced out to form mature mRNA (Stamm et al., 2005).  Four key sequences 
defining splice sites are contained within the introns.  These sequences are the 5’ and 3’ 
splice sites, the branch point region, and the polypyrimidine tract (Matlin et al., 2005; 
Stamm et al., 2005).  In 99% of all introns the first and last dinucleotides are GT and AG 
which comprise the 5’ and 3’ splice sites, respectively (Venables, 2004).  Splicing is 
assisted by the splicesome, a macromolecular ribonucleoprotein complex, whose 
assembly is guided by the conserved splice sites (Matlin et al., 2005).  The strength of a 
splice site is determined by other cis-elements including intronic and exonic enhancers 
and silencers.  The sequence variability, location, and number of cis-elements play a large 
role in determining how the RNA will be spliced.  Protein trans-acting factors associate 
with the cis-elements and affect the assembly of the splicesome to further influence the 
outcome of splicing (Matlin et al., 2005; Mauritz et al., 2007; Stamm et al., 2005).      
In 1958 George Beadle and Edward Tatum won the noble prize for their “one 
gene one enzyme” theory which held that one gene was responsible for the production of 
one enzyme in a metabolic pathway (Singer and Berg, 2004).  Over time this was 
modified to the “one gene one polypeptide” theory to account for non-enzymatic proteins 
as well as proteins composed of multiple polypeptides.  It was originally believed that the 
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human genome was comprised of over 100,000 genes.  Completion of the human genome 
project determined that fewer than 30,000 genes formed the genome, but the human 
proteome is estimated to contain over 90,000 proteins (Ast, 2004; Xing, 2007).  As 
scientists have discovered far fewer human genes than once believed, attention has turned 
to alternative splicing as a means of generating complex proteomes (Matlin et al., 2005; 
Stamm et al., 2005).  Alternative splicing refers to the different ways in which the exons 
and introns of a single pre-mRNA can be spliced together to yield several to many 
different mRNA transcripts ultimately leading to the production of multiple polypeptides 
from one gene (Venables, 2004).  There are five main types of alternative splicing:  exon 
skipping, alternative 5’ splice sites, alternative 3’ splice sites, intron retention, and 
mutually exclusive exons (Ast, 2004).  Constitutive and alternative splicing are regulated 
by the cis- and trans-elements previously discussed.  There are two main theories to 
explain alternative splicing.  Mutations in splice site sequences can lead to the use of 
weaker, alternative splice sites.  Alternative splicing can also be influenced by the types, 
combinations, and concentrations of trans-acting elements present (Ast, 2004; Matlin et 
al., 2005; Venables, 2006).        
Expressed sequence tags (ESTs) which are fragments of mature mRNA are useful 
in the identification of alternatively spliced transcripts.  ESTs as well as full length 
mRNA sequences can be aligned with genomic DNA to determine the exon/intron 
boundaries (Xing, 2007).  It is estimated that anywhere from 40 to 80% of genes are 
subject to alternative splicing (Matlin et al., 2005).  Alternative splicing has the capacity 
to influence mRNA transcript levels as well as protein binding properties, enzymatic 
activity, intracellular location, and transcript stability (Stamm et al., 2005).  Splice 
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variants can also be expressed in cellular or tissue specific manners.  At least 15% of 
genetic diseases are attributable to mutations in sites that influence splicing (Matlin et al., 
2005).  Many studies have found that alternative splicing is associated with some cancers 
(Venables, 2004; 2006).  It is possible that CES2 splice variants could be expressed in a 
tumor specific manner and therefore be responsible for the inter-individual variation that 
is seen in response to irinotecan and capecitabine treatment.    
IV. Colorectal cancer 
Colorectal cancer is the third leading cause of new cancer cases and cancer deaths 
in both men and women.  Overall, it is the fourth most frequently diagnosed cancer in the 
United States and is the second leading cause of all cancer-related deaths, following only 
lung cancer.  Colorectal cancer accounts for approximately 10% of all cancer-related 
deaths (American Cancer Society, 2007).  Depending on the grade and stage of the 
colorectal cancer, surgery, radiation and/or chemotherapy may be used for treatment.  If 
colorectal cancer is detected at an early, localized stage, surgery can successfully cure the 
disease with a five-year survival rate of 90%.  Unfortunately, only 39% of cases are 
detected at such a stage.  If the tumor has spread then chemotherapy alone or in 
combination with radiation is given as adjuvant treatment.  Regionally advanced 
colorectal cancer has a 5-year survival rate of 68% decreasing to 10% with the 
involvement of distant metastases.  Therefore, the availability of safe and efficacious 
chemotherapeutics is essential.  Over the past 50 years, 5-fluorouracil (5-FU) has been 
the most commonly used chemotherapy for the treatment of colon cancer.  Two more 
recently approved drugs for use in the treatment of colorectal cancer are capecitabine, an 
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oral prodrug of 5-FU, and irinotecan.  Both are carbamate prodrugs which are activated in 
vivo by carboxylesterases.    
Studies have shown irinotecan to be effective in the treatment of gastric, 
esophageal, and colorectal cancers.  Irinotecan has demonstrated its effectiveness as 
second-line therapy for colorectal tumors failing to respond to bolus 5-FU (Cunningham 
et al., 1998; Rougier et al., 1998).  More recent studies have shown that the combination 
of irinotecan/5-FU/leucovorin as first line chemotherapy is more effective at treating 
metastatic colorectal cancer than 5-FU/leucovorin alone (Douillard et al., 2000; Saltz et 
al., 2000).  Capecitabine can successfully replace 5-FU in combination therapy with 
irinotecan.  Capecitabine does not significantly alter the pharmacokinetics of irinotecan 
even though both enzymes are metabolized by carboxylesterases (Czejka et al., 2005).  
There is large inter-individual variation in response to treatment with irinotecan and 
capecitabine.  Addition of irinotecan to treatment regimens increases the likelihood of 
deleterious side effects.  The most common adverse effects associated with irinotecan are 
late-onset diarrhea and neutropenia.  Life-threatening Grade 4 diarrhea has been seen in 
13% of patients treated with irinotecan (Saltz et al., 2000).  The most common toxicities 
associated with capecitabine are anemia, diarrhea, and hand-foot syndrome (Walko and 
Lindley, 2005).  Inter-individual variation in both therapeutic response and adverse 
effects are likely due to a complex combination of pharmacodynamic, pharmacokinetic, 
and pharmacogenomic factors.  Variations in expression or activity of the genes 
contributing to irinotecan and capecitabine metabolism have been noted to affect drug 
distribution, metabolism, and elimination.  Methods used to study these factors include 
real-time PCR, enzyme activity assays, immunohistochemistry, and gene sequencing.  It 
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will be important to understand all aspects of the irinotecan and capecitabine pathways in 
order to make informed predictions on treatment outcome.   
V. Irinotecan 
Irinotecan is an intravenously-dosed water-soluble derivative of camptothecin 
(Chabot, 1996).  Irinotecan is metabolized by carboxylesterases and CYP enzymes found 
in the liver (Figure 4).  Carboxylesterases in the liver convert irinotecan to SN-38, a 
potent topoisomerase I inhibitor.  Irinotecan binds and stabilizes the “cleavable” 
topoisomerase I - DNA complexes.  When the topoismerase I - DNA - irinotecan 
complex meets the advancing replication fork double stranded breaks occur in the DNA 
leading to replication arrest and cell death (Liu et al., 2000).  CYP3A can oxidize 
irinotecan to NPC or APC (Dodds et al., 1998; Haaz et al., 1998; Sanghani et al., 2004).  
NPC, and to a much lesser extent APC, can then be converted by carboxylesterases to 
SN-38.  SN-38 has shown to be 1000 times more cytotoxic than irinotecan 
(Humerickhouse et al., 2000; Xu et al., 2002).  SN-38 is converted to its inactive form 
SN-38G through glucuronidation.  UDP-glucuronosyltranferase (UGT) 1A1, and possibly 
other members of the UGT1A family including UGT1A7 and UGT1A9, are responsible 
for the inactivation (Hanioka et al., 2001; Lankisch et al., 2005).  SN-38G can be 
converted back to SN-38 by endogenous β-glucuronidases (β-GUS) in the liver as well as 
by bacterial β-glucuronidases found in the gut flora.   
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Figure 4. Irinotecan (CPT-11) metabolism:  CPT-11can be oxidized to 
NPC or APC by CYP3A4.  CPT-11 is also metabolized by CES2 to the 
more active SN-38.  SN-38 is a potent topoisomerase I inhibitor.  UGT1A 
glucuronidates SN-38 to its inactive form SN-38G.  
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There is significant inter-individual variation in response to treatment with 
irinotecan (Canal et al., 1996; Couteau et al., 2000; Gupta et al., 1997).  Many labs have 
studied the importance of the various irinotecan associated enzymes:  CYP3A4 (Hanioka 
et al., 2002; Mathijssen et al., 2004; Sai et al., 2001; Santos et al., 2000), UGT1A (Carlini 
et al., 2005; Gagne et al., 2002; Hanioka et al., 2001; Innocenti et al., 2004; Jinno et al., 
2003; Lankisch et al., 2005; Tukey et al., 2002), β-GUS (Kehrer et al., 2000; Takasuna et 
al., 1996; Tobin et al., 2006), TOPO I (Guichard et al., 1999; Jansen et al., 1997; 
Pavillard et al., 2004; Sanghani et al., 2003).  Studies by our laboratory and others have 
found that CES2 may contribute to variations in response to irinotecan (Sanghani et al., 
2003; Xie et al., 2002; Xu et al., 2002).   
CES2 has higher affinity for irinotecan and a 100-fold greater catalytic efficiency 
than CES1 with respect to irinotecan metabolism (Humerickhouse et al., 2000; Sanghani 
et al., 2004).  CES2 has a 2000-fold greater catalytic efficiency than CES3 (Sanghani et 
al., 2004).  When treated with irinotecan, cells over-expressing CES2 have shown more 
cytotoxicity than cells over-expressing CES1 (Wu et al., 2002).  Due to its increased 
affinity and activity for irinotecan, CES2 is believed to be the key enzyme in vivo that 
activates irinotecan.  In patients, large inter-individual variation in response to irinotecan 
treatment has been demonstrated.  The idea has emerged that intra-tumoral 
carboxylesterase activation of irinotecan may be more important than the production of 
SN-38 by liver carboxylesterase (de Jong et al., 2006).  SN-38 levels have been shown to 
correlate with systemic toxicity but not with therapeutic effect (de Jong et al., 2007). 
There is a higher response rate in solid tumors to irinotecan as compared to other 
camptothecins.  This also suggests a role for local, intracellular activation of irinotecan, 
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because the other camptothecins are not activated by carboxylesterase (Ratain, 2000).  A 
previous study done in our laboratory found a 23-fold variation in the expression of CES2 
among 24 colorectal tumor samples (Sanghani et al., 2003).  To date there has been no 
consensus on the role of SNPs in this inter-individual variation.  In addition to wide 
variation in normal CES2 expression, we propose that expression levels and activity of 
CES2 splice variants may contribute to the inter-individual variation.   
 While carboxylesterase is important for the activation of irinotecan to SN-38, 
other factors may also contribute to the inter-individual variation in response to 
irinotecan.  Topoisomerase I activity, but not expression level, has been shown to 
correlate with irinotecan sensitivity in human colon cancer cell lines (Jansen et al., 1997). 
However, a different study using tissue samples suggested that both topoisomerase I 
activity and expression were the best predictors of response to irintocan (Pavillard et al., 
2004).  Guichard et al. (1999) showed a wide range in both topoisomerase I and 
carboxylesterase activities in colorectal carcinomas.  SN-38 undergoes glucuronidation 
by UGTs found primarly in the liver.  The wild-type UGT1A1 promoter has six TA 
nucleotide repeats in the TATA box, (TA)6TAA.  The UGT1A1*28 allele has seven TA 
repeats (TA)7TAA which results in a 70% decrease in activity of the UGT1A1 promoter 
(Ramchandani et al., 2007).  Individuals homozygous for UGT1A1*28 are the most 
affected.  A correlation between the UGT1A1*28 genotype and neutropenia has been 
demonstrated, but the correlation with diarrhea is less clear (Rouits et al., 2004).  β-GUS 
is expressed by both the body and the gut flora of the colon.  Takasuna et al. (1996) found 
β-GUS activity, but not carboxylesterase, to correlate with histological damage of the 
intestines.  Further, antibiotic inhibition of flora β-GUS decreased diarrhea.  Other studies 
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have indicated that cellular transport proteins such as P-glycoprotein and canalicular 
multispecific organic anion transporter contribute to the inter-individual variation in 
response to treatment (de Jong et al., 2007; Mathijssen et al., 2001). 
VI. Capecitabine 
Capecitabine is an oral prodrug of the anti-metabolite 5-FU (Figure 5) that was 
designed to limit the toxicities associated with 5-FU (Miwa et al., 1998).  Studies indicate 
that capecitabine can successfully replace 5-FU in chemotherapeutic regimens (Hoff et 
al., 2001; Twelves et al., 2001).  For capecitabine to be activated to 5-FU, it must 
undergo three metabolic processes.  Carboxylesterases in the liver convert 5-FU to 5’-
DFCR which is then deaminated to 5’-DFUR by cytidine deaminase.  CES1A1 and CES2 
have similar catalytic efficiencies for capecitabine hydrolysis (Quinney et al., 2005).  
Thymidine phosphorylase (TP) converts 5’-DFUR to the active drug 5-FU.  TP has 
shown to be expressed at higher levels in many tumor tissues.  Over-expression of 
thymidine phosphorylase in tumor tissues allows for greater local conversion thus 
increasing the concentration of 5-FU in tumor tissues (Budman et al., 1998; Miwa et al., 
1998; Schuller et al., 2000).  The local conversion to 5-FU by TP is responsible for the 
decrease in toxicity.  5-FU metabolites can be incorporated into active nucleotide 
metabolites.  The metabolite FdUMP targets thymidylate synthase (TS) thus lowering the 
production of thymidine.  Both RNA and DNA production are adversely affected by 
metabolites of 5-FU.  The enzyme dihydropyrimidine dehydrogenase (DPD) inactivates 
5-FU.  Patients whose tumors  express low levels of TP,TS, and DPD are more likely to 
respond to 5-FU based therapy (Ichikawa et al., 2003; Salonga et al., 2000).  However, 
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low levels of TS and DPD have also been associated with increased toxicity (Walko and 
Lindley, 2005).   
 
  
 
Figure 5. Capecitabine metabolism:  Capecitabine is an oral prodrug of 5-
FU.  Capecitabine is converted to 5’-deoxy-5-fluorocytidine (5’-DFCR) by 
carboxylesterases.  Cytidine deaminase converts 5’-DFCR to 5’-deoxy-5-
fluorouridine (5’-DFUR).  Thymidine phosphorylase which is over-expressed 
in some cancers converts 5’-DFUR to the active 5-FU.  The metabolites 
FdUMP, dFUTP, and FUTP interfere with DNA and RNA synthesis.   
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The studies of both irinotecan and capecitabine indicate complex pharmacologic 
profiles.  Factors that predict toxicity may or may not be the same factors that predict 
therapeutic outcome.  It will be important to further elucidate the pharmacogenomic 
profiles of each enzyme or drug transporter involved in the metabolism of these drugs.  
The data should then be used together to tailor chemotherapy for the best outcomes.    
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VII. Research objectives 
It is our hypothesis that the expression levels and activities of the CES2 splice 
variants will correlate with irinotecan and capecitabine activation in tumor and normal 
tissue.  We expect to characterize the expression and activity of the carboxylesterase 2 
gene and its splice variants (Aim #1 and #2). We also plan to examine the expression 
levels of other enzymes in the metabolic pathways of irinotecan and capecitabine (Aim 
#3).  We expect that our research will lead to better understanding of chemotherapy by 
aiding clinicians in identifying patients that will benefit the most while enduring the 
fewest number of side effects.  While this project focuses mainly on CES2 in relationship 
to colorectal cancer, its findings may be applicable to other cancers whose treatments 
include irinotecan or capecitabine.        
Aim #1:  Understand the expression patterns of the CES2 splice variants 
a. Tissue-specific expression 
b. Variant expression and activity in colorectal tissue 
Aim #2:  Characterization of CES2 variant proteins 
a. Cloning and expression of CES2 splice variants 
b. Activity of recombinant CES2 variant proteins 
c. Sub-cellular localization of CES2 variants 
Aim #3:  Evaluate the role of CES2 variants and other enzymes in the inter-individual 
variation in response to treatment of colorectal cancer with irinotecan and capecitabine. 
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METHODS 
I. Materials 
The Human 12-lane Multiple Tissue Northern (MTN) blot was purchased from 
Clontech (Palo Alto, CA) by Dr. Eileen Dolan.  All radioactive nucleotides were from 
Perkin Elmer (Waltham, MA).  The Random Primed DNA Labeling Kit and G-50 Quick 
Spin columns were from Roche Diagnostics (Indianapolis, IN).  The Ultrahyb Solution 
was ordered from Ambion (Austin, TX).  The RNeasy Plus Mini Kits, QIAshredders, the 
Allprep DNA/RNA kits, and QIAquick PCR Purification Kit were from Qiagen 
(Valencia, CA). Disposable mortars and pestles were purchased from Kontes.  The 
GeneAmp Gold RNA PCR kits and SYBR Green kits were purchased from Applied 
Biosystems (Foster City, CA).  All primers were ordered from Integrated DNA 
Technologies (Coralville, IA).  The Zero Blunt TOPO PCR cloning kit was from 
Invitrogen (Carlbad, CA).  The Sf9 insect cell and media was also from Invitrogen 
(Carlsbad, CA).  Irinotecan was a gift from Dr. Patrick McGovern, Pharmacia-Upjohn 
Corporation (Peapack, NJ).  Oasis HLB solid phase columns were from Waters (Milford, 
MA).  Calf intestine alkaline phosphatase was from New England Biolabs (Ipswich, 
MA).  Pfu Pyroglutamate Aminopeptidase was purchased from Takara (Otsu, Shiga, 
Japan).  Protein standards and DEAE Affi-Gel blue  were from Bio-Rad Labs (Hercules, 
CA).  Baculogold DNA and the transfer vector were from BD-Pharmingen (San Diego, 
CA).  Vectashield was from Vector Laboratories (Burlingame, CA).  General chemicals 
and supplies were ordered from Sigma Chemical (St. Louis, MO) or Fisher Scientific 
(Pittsburgh, PA). 
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II. Tissue-specific expression of CES2 splice variants 
Northern analysis 
A Human 12-lane Multiple Tissue Northern (MTN) blot (Clontech) with normal 
tissue (Figure 6) (Wu et al., 2003) was probed with cDNA probes specific for CES2+64 
and CES2∆1-93.  CES2+64 had been cloned into the pVL1392 vector (described in Methods 
Section V).  To construct the CES2+64 cDNA probe, approximately 40 µg of the CES2+64-
pVL1392 vector was digested with Bgl II and Xma I.  The digested vector was 
electrophoresed on a 1% agarose gel.  An approximately 130 bp fragment was excised 
and gel purified (Qiagen).  To construct the CES2∆1-93 probe, the GeneAmp Gold RNA 
PCR kit (Applied Biosystems) was used to amplify the cDNA.  The primers 5’-
GACAGGGACCGGGCTCAGATCT-3’ (sense) and 5’-TGTACTCCGCTGGTTCC 
TTGCC-3’ (antisense) amplified a 210 bp from intron 1 of CES2.  The reaction contained 
colon tumor cDNA as the template and 0.3 µM of each primer.  The reaction conditions 
were 95°C for 10 minutes; 35 cycles of 95°C for 30 sec, 63°C for 30 sec, and 72°C for 1 
min, followed by 72°C for 7 minutes.  The PCR product was electrophoresed on a 1% 
agarose gel.  A 210 bp product was excised and gel purified (Qiagen).   
For both CES2+64 and CES2∆1-93, approximately 15 ng of probe were labeled with 
[α-32P]-CTP using the Random Primed DNA Labeling Kit (Roche Diagnostics).  
Unincorporated radionucleotides were separated from the labeled probe with the G-50 
Quick Spin columns (Roche).  Labeled probe was mixed with 50 µl of sonicated salmon 
sperm, denatured and added to the blot which had been pre-hybridized for approximately 
75 min at 42°C with Ultrahyb Solution (Ambion).  The blot was hybridized overnight.   
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The blot was then washed two times for 15 minutes at room temperature with 2x SSC 
containing 0.1% SDS followed by two 30 minute wash at 58°C and one 10 minute wash 
at 60°C with 0.1x SSC containing 0.1% SDS.  The blot was exposed to a phosphor-
storage screen at room temperature for 4-5 days.    
 
 
 
 
 
Figure 6. Multiple Tissue Northern (MTN) blot analysis  
  (Wu et al., 2003) 
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III. Analysis of CES2 and CES2∆458-473 in paired tumor and normal colon samples 
Colon tissue  
The collection and use of these samples was approved by the Indiana University 
Institutional Review Board.  The tumors were primary colon carcinomas of various 
grades and stages from all segments of the colon (Table 3).  Normal colon specimens 
were paired with each tumor sample.  All specimens were surgery samples that were 
reviewed by a pathologist.  All samples were immediately frozen in liquid nitrogen and 
maintained at -70°C until use.  
 
Sample  Site  Diagnosis  Stage  
T1 Sigmoid colon  Adenocarcinoma  
T2  Right/transverse 
colon  
PD Mucinous 
Adenocarcinoma  
 
T3  Sigmoid colon  MD  Adenocarcinoma pT3, N0, MX 
T4  Colon  MD Adenocarcinoma pT3, N0, MX 
T5  Colon  MD Adenocarcinoma pT3, N2, MX 
T6  Sigmoid colon  MD Adenocarcinoma pT3, N1, MX 
T7  Transverse 
colon  
PD Adenocarcinoma pT4, N1, MX 
T8  Cecum  MD Adenocarcinoma pT3, N2, MX 
T9  Right colon  MD Adenocarcinoma  
T10  Sigmoid colon  MD Adenocarcinoma pT2, N0, MX 
 
Table 3. Colon tumor samples:  Each tumor sample was paired with a 
normal colon sample originating from a segment of the colon.  MD and 
PD represent moderately- and poorly- differentiated, respectively.  
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RNA isolation and reverse transcription 
Tissues, ~5-30 mg, were disrupted in RLT Buffer (Qiagen) using a disposable 
mortar and pestle (Kontes).  Disruption was followed by homogenization via 
QIAshredder columns (Qiagen).  Total RNA was isolated using the RNeasy Plus Mini 
Kit (Qiagen).  RNA was quantified using a ND-1000 Spectrophotometer (Nanodrop).  
RNA quality was assessed by running 500 ng of total RNA on a 1% agarose gel. The 
GeneAmp Gold RNA PCR kit (Applied Biosystems) was used for reverse transcription 
with 1μg of total RNA added to a 50-μl reaction.  The reaction components were 2.5 mM 
MgCl2, 250 µM of each deoxynucleotide triphosphate, 1.25 µM oligodeoxythymidylic 
acid primer, 0.5 U/µL RNase inhibitor, and 0.75 U/µL MultiScribe reverse transcriptase.  
The reaction conditions were room temperature for 10 min, 42°C for 60 min, 68°C for 10 
min, and 95°C for 5 min.  All reverse transcription reactions were verified by PCR using 
the GeneAmp Gold RNA PCR kit (Applied Biosystems) and primers for GAPDH.  The 
GAPDH primers were 5’-GACCACAGTCCATGCCATCACT-3’ (sense) and 5’-
TCCACCACCCTGTTGCTGTAG-3’ (antisense).  A 20 μL PCR reaction contained 1x 
buffer, 1.75mM MgCl2, 0.8mM of each deoxynucleotide triphosphate, 0.375 μM of each 
primer, 1 µl of reverse transcription reaction, and 0.05U/ μL AmpliTaq Gold.  The 
reaction conditions were 95°C for 10 min; 35 cycles of 95°C for 30 s, 63°C for 30 s, and 
72°C for 1 min, followed by 72°C for 5 min.  The GAPDH product size was ~450 bp.  
Real-time PCR 
This real-time PCR protocol has been modified from that previously published 
(Sanghani et al., 2003) to distinguish between CES2 and CES2∆458-473 variants. Variant-
specific forward primers were designed for CES2, 5’-CCATGGTGATGAGCTTCCTT 
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TTGT-3’, and CES2∆458-473, 5’-AGGCAGACCATGTTAAATTCACTGA-3’.  The 
reverse primer 5’-AGGTATTGCTCCTCCTGGTCGAA-3’ was common to both 
transcripts. The expected lengths of the PCR products were 186 bp and 145 bp for CES2 
and CES2∆458-473, respectively.  The PCR conditions were 3 mM Mg+2, 0.5 μM of each 
primer, 0.2 mM of deoxynucleotide triphosphates using the SYBR Green kit (Applied 
Biosystems).  The cDNA equivalent to 20 ng of RNA was added to each 25 μl PCR 
reaction.  PCR cycling conditions were 50°C for 2 min, 95°C for 10 min and 40 cycles of 
95°C for 30 s, 65°C for 30 s, and 72°C for 1 min on an Eppendorf Mastercycler EP 
instrument.  The uniformity of the PCR products was determined using the melt curve 
function.  A standard curve for each gene was generated using clones that were 
constructed in our laboratory.  The copy numbers of each variant present in the tissues 
were determined by comparison to the appropriate standard curve.  All cDNA samples 
were analyzed in triplicate for each gene.    
Tissue lysate preparation  
Approximately 10-60 mg of colon tissue were homogenized in 100-200 µl of 25 
mM KH2PO4, pH 7.5, plus 0.05% Triton X-100, leupeptin (10 μg/mL), pepstatin (1 
μg/mL) and DNase (0.5 μg/mL) using motorized pestles with microfuge tubes (Kontes).  
Disrupted samples were incubated on ice for approximately 20 minutes before a final 
round of homogenization.  The lysates were centrifuged at 40,000 x g for 15-20 min at 
4°C.  The supernatant was collected for use in activity assays.  Protein content was 
quantified via the Bio-Rad Protein Assay with bovine serum albumin used for a standard 
curve.  
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4-Methylumbelliferyl acetate hydrolysis assay  
Brzenzinski et al. (1997) have previously described the use of 4-
methylumbelliferyl acetate (4-MUA) in spectrophotometric assays to measure non-
specific carboxylesterase activity.  Ten microliters of lysate were incubated with 0.5 mM 
4-methylumbelliferyl acetate at 37°C in a buffer containing 90 mM potassium phosphate 
buffer and 40 mM KCl (pH 7.4) The rate of formation of 4-methylumbelliferone (4-MU) 
was monitored at 350 nm.  4-methylumbelliferone has an extinction coefficient of 12.2 
mM-1 cm-1.  Specific activity was calculated using the results of the 4-MUA assay and the 
Bio-Rad protein assay.  Units of specific activity were in μmol mg-1 min-1.  Each lysate 
sample was run in duplicate.   
Analytical non-denaturing polyacrylamide gel electrophoresis 
The colon lysates were run on analytical discontinuous non-denaturing PAGE as 
previously described by Dean et al. (1995).  Approximately 50 to 100 μg of lysates were 
run, as well as 0.8 μg purified CES2 and 1.0 µg CES1 as controls.  To detect 
carboxylesterase activity, the gels were incubated with a solution of 1 mM 4-MUA in 100 
mM potassium phosphate buffer pH 6.0 for 10 minutes.  The product 4-MU was detected 
under UV light, and gel images were captured using the Gel Doc 1000 system (BioRad).  
Densitometry analysis was done using Quanity ONE version 1 (BioRad).  To account for 
differences between gels, the band density values were normalized to the CES2 density 
on the corresponding gel.   
Statistical analysis 
Skewness, kurtosis, and overall normality of copy number, 4-MUA hydrolase 
activity and band density data were assessed using the methods of D’Agostino et al. 
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(1990).  The copy numbers for each variant were independently subjected to linear 
regression analysis against both 4-MUA hydrolase activity and band density using JMP 
4.0 (SAS Inst Inc., Cary, NC).  The data were considered significant if p < 0.05. Susan 
Perkins from the Indiana University Cancer Center performed the kurtosis analysis. 
IV. Characterization of the CES2Δ458-473 variant   
Cloning, expression, and purification of the CES2Δ458-473 variant   
The CES2Δ458-473 variant was cloned by Dr. Sonal Sanghani and virus production 
was completed by Scheri-lyn Green.  Briefly, a partial EST clone for CES2Δ458-473 was 
obtained from ATCC (Image Clone ID 6195662).  The CES2Δ458-473 EST clone and a 
CES2 clone in the pVL1392 vector were both digested with Xba I and Sma I restriction 
enzymes.  The Xba I/Sma I CES2Δ458-473 fragment was ligated into the digested CES2-
pVL1392 vector.  The new CES2Δ458-473-pVL1392 clone was sequenced to confirm the 
presence of the 48 bp deletion.    
The CES2Δ458-473 protein was expressed using the baculovirus system (BD 
Biosciences Pharmingen) as previously reported (Sanghani et al., 2004; Sun et al., 2004).  
The CES2Δ458-473-pVL1392 vector was co-transfected with linearized Baculogold DNA 
(BD-Pharmingen) into 2.5 x 106 Sf9 cells following the manufacturer’s protocol.  The 
CES2∆458-473 recombinant virus was collected on day 8, post-transfection.  Sf9 insect cells 
were infected with CES2∆458-473 recombinant virus.  After 70 hours, the cells were 
collected by centrifuging at 500 x g for 5 min.  The cell pellet was sonicated in 30 ml of 
20 mM Tris buffer, pH 7.4, containing 1 mM benzamidine, 1 mM dithiothreitol, 1μM 
leupeptin and 0.1% Triton X-100. The cell lysate was ultracentrifuged at 100,000 x g for 
45 min.  The recombinant CES2Δ458-473 variant was purified by a two step purification 
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protocol (Sanghani et al., 2004) using concanavalin A affinity chromatography and 
preparative non-denaturing PAGE (Sun et al., 2004).  A protein peak was detected at the 
same position as CES2; however, it did not have any activity for the substrate 4-
methylumbelliferyl acetate.  Fractions from this peak were concentrated and loaded onto 
an 8.5 cm 6% non-denaturing preparative polyacrylamide gel as described earlier (Sun et 
al., 2004).  A protein peak eluting similarly to CES2 was detected, and the eluted 
fractions corresponding to protein peak were pooled and concentrated.   
The purified recombinant CES2Δ458-473 protein was analyzed by SDS-PAGE, 
western blot analysis, non-denaturing gel electrophoresis, mass spectroscopy, and circular 
dichroism to assess its identity, purity, and physical properties.  Antibodies for the 
western blotting were raised in rabbit to the deglycosylated human CES2 protein.  The 
antibody was purified from 8 ml of serum using the DEAE Affi-Gel blue (Bio-Rad Labs) 
according to the manufacturer’s protocol.  The purified anti-CES2 antibody was diluted 
5000-fold, and the secondary antibody was HRP-conjugated.  Circular dichroism (CD) 
spectra for the proteins were determined using a J-720 spectropolarimeter (Jasco).  The 
spectra were then analyzed using the CDPro software developed by Sreerama and Woody 
(Sreerama and Woody, 1993; Sreerama and Woody, 2004)  Dr. Sonal Sanghani and 
Wilhelmina Davis purified the protein. Wilhelmina Davis completed the gels, protein 
assays, and activity assays.  Dr. Paresh Sanghani completed the CD analysis. 
CPT-11 hydrolysis assay  
The CPT-11 hydrolysis assay has previously been described by Sanghani et al. 
(2004).  In 250 µl reactions, 55µM CPT-11 was incubated with varying amounts of CES2 
(0-30 µg) and CES2∆458-473 (0-50 µg) in 50 mM HEPES buffer, pH 7.4, including 10% 
31 
ethylene glycol at 37°C for 30 minutes and two hours, respectively.  The reactions were 
halted by the addition of 670 µl of 0.1 M HCl.  Fifteen µl of 0.14 mM camptothecin was 
added as an internal standard to the reactions.  Samples were extracted on Oasis HLB 
solid phase columns (Waters) and were prepared as previously described (Sanghani et al., 
2004).  The samples were injected onto a 5 µm C18, 150 x 4.6 mm Luna column 
(Phenomenex).  The mobile phase consisted of 28.5% acetonitrile in 0.1M KH2PO4, pH 
4.0, with 3mM heptane sulfonic acid.  The samples were eluted at a flow rate of 1 ml/min 
and then detected via fluorescence (excitation=375nm, emission=560nm).  SN-38 
samples (0-5 µM) were treated in a similar manner and used to create a standard curve.  
The ratios of area under the curve for SN-38 and camptothecin were plotted against 
concentration (GraphPad Prism 4.0).  The unknown concentrations were calculated from 
the standard curve.      
V. Characterization of the CES2+64 variant  
Cloning of the CES2+64 variant 
The forward 5’-ATCAGATCTATGACTGCTCAGTCCCGCTCT-3’and reverse 
5’-GACCTAGAGGTGGCTTGGCAAAT-3’ primers were designed to amplify 
approximately 400 bp corresponding to the N-terminal sequence for CES2+64.  The 
forward primer added a Bgl II site (underlined) and contained the ATG (bold) translation 
start site for CES2+64.  The reaction contained 0.6 μM of each primer, 0.2 mM of each 
nucleotide, 1 μl of human liver cDNA, 1x pfu native buffer, and pfu native enzyme.  The 
reaction conditions were 95° C for 4 min, 5 cycles of 95°C for 30 s, 60°C for 30 s, and 
72°C for 1.5 min, followed by 35 cycles of 95°C for 30 s and 72°C for 1.5 min.  This was 
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followed by a final extension time of 5 min at 72°C.  The PCR product was run on a 1% 
gel to verify the size.  Scheri-lyn Green completed the PCR for CES2+64 cloning.  
 The remaining PCR product was purified using the QIAquick PCR Purification 
Kit.  The Zero Blunt TOPO PCR cloning kit (Invitrogen) was used as per the given 
protocol to clone the purified PCR product into the pCR-Blunt II-TOPO vector 
(Invitrogen).  Ligation was followed by transformation into One Shot TOP10 chemically-
competent E. coli (Invitrogen).  The transformed bacteria were plated on LB plates 
containing 50 μg/ml kanamycin.  Four colonies were selected for overnight cultures, 5ml 
each with 50 μg/ml kanamycin.  Plasmids were isolated by miniprep (Qiagen) followed 
by digestion with Eco RI.  The digests were analyzed by 1% agarose gel, and all four 
clones yielded the expected digestion pattern. 
One and a half ug of both the +64 insert in the pCR-Blunt II-TOPO vector and 
CES2 in the pVL1392 baculovirus transfer vector were subject to overnight digestion 
with Bgl II and Aar I at 37°C.  The digestions were analyzed on a 1% agarose gel.  A 300 
bp band from the +64-pCR Blunt II-TOPO clone was gel-purified using the QIAquick Gel 
Extraction Kit.  The linearized CES2-pVL1392 vector was incubated with 1 μL of calf 
intestine alkaline phosphatase (NEB) at 37°C for one hour after which it was purified 
using the QIAquick PCR purification kit.  The 300 bp insert (2.1 µl) and the 
dephosphorylated vector (2.2 μl) were incubated with Fast-link DNA ligase (Fastlink, 
Epicenter) for 15 minutes at room temperature.  The ligation reaction was transformed 
into TOP10 E. coli which were plated on a LB plate containing 50 μg/mL ampicillin.  
Two colonies were amplified in 5 ml overnight cultures with 50 μg/mL ampicillin.  From 
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the overnight cultures, 150 µl were used to inoculate 100 ml overnight cultures.  Plasmids 
were isolated by midiprep (Qiagen).  Restriction digests of the clones with Bgl II and  
Aar I yielded the expected digestion pattern.  These clones were submitted for sequencing 
to the Biochemistry DNA Sequencing Core.  The forward cloning primer and the reverse 
primer 5’-TGCAAATCGCAGCGGACCTAGA-3’ were used for sequencing.  Sequences 
of the clones were aligned with the expected CES2+64 sequence using the DS gene 
software. 
Production of the recombinant CES2+64 virus 
Two and one-half μg of the CES2+64-pVL1392 vector were co-transfected with 0.5 
μg of linearized Baculogold viral DNA (BD-Pharmingen) into 2.5x106 Sf9 insect cells 
following the manufacturer’s protocol.  One week post-transfection, the media containing 
the recombinant CES2+64 virus was collected.   
Plaque assays were performed to obtain a more virulent virus.  Approximately 
6x106 Sf9 insect cells were plated per 100-mm dish.  The cells were infected with 1 ml 
viral dilutions (10-4, 10-5, 10-6, and 10-7), each in duplicate.  After one hour, the media 
was removed and the cells were overlaid with a 1% agarose solution in TNM media plus 
1x penicillin/streptomycin.  The plates were incubated at 27°C for about 2 weeks until 
plaques were visualized.  Eleven plaques were selected, and plaque plugs were collected 
through sterile pipetting.  The plugs were added directly to separate wells of a 12-well 
plate seeded with Sf9 cells at a density of 3x105 cells/well.  One well was left uninfected 
as a control.  The plate was placed at 27°C for 12 days after which the media from each 
well was collected separately as passage 1 (P1).  
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Viral DNA for each sample was isolated from 750 µl of P1 stock.  PCR was 
completed to confirm the presence of CES2+64 viral DNA.  PCR reactions were set up 
using the GeneAmp RNA PCR core kit (Applied Biosystems).  Each twenty-five µl 
reaction contained 1x buffer, 2 mM MgCl2, 0.2 mM of each deoxynucleotide 
triphosphate, 0.3 µM of each primer (same as those used for sequencing), 12.5 U 
AmpliTaq, and 1 µl template DNA.  For positive and negative DNA template controls, 
CES2+64-pVL1392 and CES2-pVL1392 were used, respectively.  The reaction conditions 
were 95° C for 4 min, 5 cycles of 95°C for 30 s, 60°C for 30 s, and 72°C for 1.5 min, 
followed by 35 cycles of 95°C for 30 s and 72°C for 1.5 min.  The PCR products were 
electrophoresed on an agarose gel.  If the template DNA contained the sequence for 
CES2+64, the expected PCR product size was approximately 430 bp.  Nine of the eleven 
viruses yielded the correct band.  One recombinant virus containing the CES2+64 DNA 
was selected for future use in the expression of CES2+64.  One hundred µl of the selected 
P1 virus was used to infect 6x106cells Sf9 insect cells in T75 flasks.  The cells were 
incubated at 27°C for 9 days.  The media was collected for the passage 2 (P2) virus.  A 
passage 3 (P3) viral stock was made by infecting 400 ml of Sf9 cells seeded at 2x106 
cells/ml with 8 ml of P2.  P3 was collected after 9 days. 
Purification of the CES2+64 variant protein  
The CES2+64 variant protein was expressed and purified in the Protein Expression 
Core by Lan Min Zhai.  A one liter culture of Sf9 cells (~2x106cells/ml) was each 
infected with 20 mL of P3 virus.  Approximately 65 hours post-infection, the cultures 
were combined and centrifuged for 5 minutes at 500 x g.  The media was collected and 
the cell pellet was stored for later use.  The recombinant CES2+64 protein was tagged with 
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a C-terminal His-tag, and nickel affinity resin was used in the purification procedures.  
The protein was eluted from the nickel resin with 60 mM imidazole.  Protein was purified 
from the media fraction and the cell pellet, separately.  The purified protein was buffered 
exchanged, and the final buffer was 20 mM Tris, pH 7.5 plus 1 mM benzamidine and 
10% ethylene glycol.  The amount of protein was quantified using the Protein the Bio-
Rad Protein Assay with bovine serum albumin used for a standard curve.  The purity of 
the protein, from the media and the cells, was analyzed by SDS-PAGE followed by 
Coomassie Blue staining.   
4-Methylumbelliferyl Acetate Hydrolysis Assay  
Carboxylesterase activity was determined by 4-MUA hydrolysis as discussed 
previously.  Briefly, 5 to 10 µl of recombinant CES2+64 protein, isolated from the media 
and cells, was incubated with 0.5 mM 4-methylumbelliferyl acetate in 90 mM potassium 
phosphate buffer with 40 mM KCl (pH 7.4) at 37°C.  The rate of formation of 4-MU was 
monitored at 350 nm.  Specific activity (μmol mg-1 min-1) was calculated from the results 
of the 4-MUA assay and the Bio-Rad protein assay.  Samples were analyzed in duplicate.   
Analytical non-denaturing polyacrylamide gel electrophoresis 
Purified CES2+64 proteins were analyzed by analytic non-denaturing 
polyacrylamide gel electrophoresis as previously described by Dean et. al. (1995).  
Purified CES2+64 protein (0.1-0.2 µg) and CES2 protein (0.1 µg) were loaded onto an 8% 
non-denaturing polyacrylamide gel.  The samples were electrophoresed for 2 hours at 
4°C after which the gel was incubated with 1 mM 4-MUA in 100mM potassium 
phosphate buffer pH 6.0 for 10 minutes.  The Gel Doc 1000 system (BioRad) was used to 
capture the gel image.  After imaging the gel was denatured and transferred to an 
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Immobilon-P membrane for western blotting.  The western blotting procedure was the 
same as described below for the SDS-polyacrylamide gels.  A separate non-denaturing 
PAGE was run followed by Coomassie blue staining to visualize the proteins.  
SDS-Polyacrylamide gel electrophoresis and western blot analysis 
 Samples of CES2+64 protein, purified from media and cells, were electrophoresed 
long 8% SDS polyacrylamide gels at 100 to 150 volts.  To visualize the proteins, one gel 
was stained with Coomassie blue.  The proteins from another gel were transferred onto 
Immobilon-P membrane through semi-dry transfer for one hour.  The western blotting 
protocol was similar to that described in Methods Section II.       
Glycosylation analysis of CES2+64    
 CES2+64 protein, purified from the media and cells, was electrophoresed on an 8% 
non-denaturing polyacrylamide gel at 15 mA for 2 hours at 4°C.  Purified CES2 was 
loaded on the gel as a control.  The gel was denatured for 30 min in a 1% SDS solution 
with 20% MeOH and 2% β-ME. The proteins were transferred onto Immobilon-P 
membranes (Millipore) by semi-dry transfer for one hour.  Transfer was detected with 
Ponceau S.  The DIG Glycan Differentiation Kit and protocol (Roche) were used to 
determine the glycosylation state of the proteins.  The membrane was blocked overnight 
at 4°C.  All of the remaining steps were completed at room temperature.  The membrane 
was washed two times with Tris buffered saline (TBS) and one time with TBS plus 1 mM 
MgCl2, 1 mM MnCl2, 1 mM CaCl2, pH 7.5 (Buffer 1) for 10 minutes each.  The blot was 
incubated with a 1:1000 dilution of digoxigenin-labeled Galanthus nivalis agglutinin 
(GNA) in Buffer 1 for one hour.  The incubation was followed by three 10 minute washes 
with TBS.  The blot was then incubated with a 1:1000 dilution of anti-digoxigenin-AP in 
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TBS.  After one hour, the blot was washed 3 times for 10 minutes with TBS.  
Glycosylation was visualized with NBT/X-phosphate in 0.1 M Tris-HCl, 0.05 M MgCl2, 
0.1 M NaCl, pH 9.5.   
N-terminal Sequencing 
Approximately 11 µg of CES2+64 purified from media and 57 µg of CES2+64 
purified from cells were electrophoresed on 8% SDS-polyacrylamide and non-denaturing 
polyacrylamide gels, respectively.  The non-denaturing gel was incubated with 
denaturing solution for 30 minutes followed by washes with water.  Proteins from both 
gels were transferred onto Immobilon-P membranes through semi-dry transfer.  The blots 
were placed in Coomassie (0.1% Brilliant Blue, 50% methanol, 10% acetic acid) for 10 
minutes.  The blots were destained with 50% methanol plus 10% acetic acid for 10 
minutes followed by 10 quick rinses with water.  The blots were stored at room 
temperature until further use.   
Pham et al. (2005) described an on-membrane enzymatic cleavage method for use 
prior to N-terminal sequencing.  Four desired protein bands were excised from the blots 
and placed into microfuge tubes.  The excised bands of membrane were wet with 
methanol and rinsed ten times with water.  The bands were blocked in a solution of 0.5% 
Zwittergent 3-16 (Sigma) in 0.1 M Tris, pH8 for 5 minutes, shaking at room temperature.  
The bands were then placed into fresh microfuge tubes and were washed 10 times with 
water.  Each band was incubated with 1.97 mU Pfu Pyroglutamate Aminopeptidase 
(Takara) in 50 mM sodium phosphate with 10 mM DTT and 1 mM EDTA at 75°C for 2 
hours.  The bands were rinsed 10 times with water and allowed to dry.  N-terminal 
sequencing was completed by Cambride Peptides (Birmingham, West Midlands, UK) 
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using the Edman degradation process.  Each band was processed for five rounds of 
sequencing.  
VI. Sub-cellular localization of CES2 variants 
Cloning of pEGFP-CES2+64 
Figure 7 outlines the cloning strategy for pEGFP-CES2+64.  A chimera was 
designed to include the N-terminal portion of the variant including both ATGs and the 
signal peptide, EGFP, and the C-terminal ER retention signal of CES2.  The N-terminal 
sequencing region of CES2+64 was amplified using the forward primer 5’-ATCAGATCT 
ATGACTGCTCAGTCCCG-3’ and the reverse primer 5’-GTCGACTCCGGATGGGACT 
GGCTGAGTC-3’.  The CES2+64 sequence is shown in italics.  Bgl II and Sal I sites 
(underlined) have been added to the forward and reverse primers, respectively.  The 
forward primer was previously used in cloning CES2+64 into the pVL1392 vector.  This 
clone was used as template for the N-terminal amplification.  EGFP was amplified using 
the forward primer 5’-AGCTCAAGCTTCGAATTC TGCAGTCGACGG-3’ and the 
reverse primer 5’-GCGGCCGCCTACAGCTCTGTGTGCTTGTAC-3’ and pEGFP-N2 
as the template.  The forward primer contains a Sal I site (underlined).  The reverse 
primer introduced a Not I site (underlined) and the HTEL C-term of CES2 (italicized).  
Both of the PCR products were cloned into an E. coli replication vector by blunt-end 
ligation followed by transformation into TOP10 E. coli.  Colonies were selected for 
overnight culture.  The recombinant vectors were isolated by Qiagen mini-prep and then 
digested with the appropriate enzymes.  pEGFP-N2 was digested with Bgl II and Not I 
followed by dephosphorylation.  The three pieces (N-term CES2+64, EGFP+HTEL, and 
the linearized pEGFP-N2 vector) were then ligated and transformed into TOP 10 E. coli.  
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Clones were selected and grown for mini-preps.  The DNA construct was then confirmed 
by sequencing.  
 
 
  
 
Figure 7. Strategy for cloning the pEGFP-CES2+ 64 construct:  The N- and C-
termini of CES2+ 64 are added to the N-and C-termini of EGFP, respectively. 
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Cloning of pEGFP-CES2 
A pEGFP-CES2 was constructed in a similar manner as pEGFP-CES2+64.  
Briefly, the N-terminal coding sequence of CES2 was amplified with the forward primer 
5’-AGATCTATGCGGCTGCACAGACTTCGTGCGCGGCTG-3’ and the same reverse 
primer used to amplify the N-terminus of CES2+64.  The forward primer which was used 
to clone CES2 into the pVL1392 vector contains a Bgl II restriction enzyme cut site 
(underlined) and the CES2 ATG and sequence (bold, italicized).  The PCR product was 
then blunt-end ligated and digested as stated above.  The PCR for the EGFP-HTEL 
construct did not have to be repeated.  The pEGFP-CES2+64 clone was digested with  
Bgl II and Sal I as was the CES2 N-term in the TOPO vector.  The CES2 N-term 
sequence was ligated into the digested pEGFP-HTEL vector to make the final construct 
pEGFP-CES2. 
Cloning of pEGFP- CES2Δ1-93    
Because the N-terminal sequence of CES2Δ1−93 is not unique to this protein and is 
not believed to contain any signal sequences, the entire CES2Δ1-93 sequence needed to be 
cloned into the pEGFP vector.  The forward primer which was used to clone CES2Δ1-93 
into the pVL1392 vector was 5’-TGGAAGATCTATGTGTCTACAGGACC-3’ and the 
reverse primer was 5’-GTCGACTTCTCTCTTCAGGCTCCTCG-3’.  The forward 
primer contained a Bgl II site (underlined), and the reverse primer introduced a Sal I site 
(underlined).  pEGFP- CES2Δ1-93was made in a similar manner to pEGFP- CES2 (above).  
The construction of all pEGFP-CES2 variant plasmids was completed by Lan Min Zhai 
in the Protein Expression Core. 
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Transfection of GFP constructs  
HCT-15 cells were seeded at ~3x105 cells per 2 ml on poly-L-lysine treated cover 
slips placed in 35mm dishes.  The cells were incubated at 37°C with 5% CO2 for one to 
two days.  Transfections were completed using the FuGene6 reagent (Roche) in a 3:1 
ratio with 2 µg of DNA.  Six µl of FuGene were added to a volume of Opti-MEM media 
(Invitrogen) that yielded a final volume of 100 µl after the addition of DNA.  The 
FuGene-media mixture was incubated at room temperature for 5 min.  A volume of DNA 
equivalent to 2 µg was added, and the new mixture was incubated for 20 min at room 
temperature.  After removing the media, the transfection solution was added to the cells 
on the cover slip.  The cells were incubated at 37°C, 5% CO2 for approximately 5-10 
minutes after which 2 mls of fresh RPMI (Cambrex) media with 10% FBS and 1% 
pen/strep was added.  The production and localization of the chimeric GFP proteins was 
followed over a 24-48 hour period using the Axiovert 200 microscope (Zeiss).  The GFP 
transfections and the immunostaining assays were completed by Sharry Fears.     
VII. The role of CES2, CES1, TOPO I, TP, TS, DPD, β-GUS, and UGT1A1 in the 
inter-individual variation in response to treatment of rectal cancer with irinotecan 
and capecitabine 
Patients were evaluated and treated as per the HOG GI03-53 protocol (outlined 
briefly in Figure 8).  Pre-treatment biopsy samples and post-treatment surgery samples of 
normal and tumor tissue were collected and immediately frozen.  All specimens were 
reviewed by a pathologist.  The biopsy samples ranged from ~2 to 20 mg while the 
surgery samples were significantly larger.  RNA and genomic DNA were isolated from 
eleven biopsy samples for analysis.  RNA was collected from eleven biopsy samples in  
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Figure 8. Outline of the strategy for rectal samples collected for the GI03-53 study 
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the manner described in Methods section III.  Genomic DNA as well as the total RNA 
was collected from either a biopsy sample or corresponding surgery sample for each of 
the eleven patients using using the Allprep DNA/RNA kit (Qiagen).  All tissued samples 
were stored at -70°C.   
Clinical methods and data collection 
All clinical data were collected by other members of the HOG GI03-53 team.  
Clinical endpoints included tumor response and toxicity.  After receiving their course of 
chemotherapy, patients were noted as having a pathological complete response (pCR) or 
a pathological non-complete response (pNCR).   
Reverse transcription and real-time PCR 
Methods similar to those described in Methods section III were employed.  
Reaction volumes at times differed from Methods section III; however, concentrations 
remained the same.  RNA quality was not assessed by gel electorphoresis.  Real-time 
PCR was completed for CES2, CES1, topoisomerase I (TOPO I), thymidylate synthase 
(TS), thymidine phosphorylase (TP), β-glucuronidase (β-GUS), and dihydropyrimidine 
dehydrogenase (DPD).  Clones were constructed for each of these genes for the use in 
creating standard curves.  The primers used for cloning (excluding CES1 and CES2) and 
real-time PCR are listed in Table 4.  All PCR products were checked by sequencing.  The 
product sizes and plasmids are listed in Table 5.   
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Gene Primers 
Conc. 
primer 
(µM) 
Melting  
time 
at 950C 
(sec) 
Annealing 
 time 
at 650C 
(sec) 
Extention 
time 
at 720C 
(sec) 
CES2  F 5’-CCATGGTGATGAGCTTCCTTTTGT-3’  0.5 30 30 60 
 R  5’-AGGTATTGCTCCTCCTGGTCGAA-3’      
CES1 F 5’- AGAGGAGCTCTTGGAGACGACAT-3’ 0.2 30 30 60 
 R 5’- ACTCCTGCTTGTTAATTCCGACC-3’     
TOPO I  F 5’-CGTTCTACCAGGCAAATTCACTGT-3’  0.3 20 15 40 
 R 5’-TGAAATGGGAGAGAGGGAAGGGA-3’      
β-GUS  F 5’-TCAACAAGCATGAGGATGCGGAC-3’  0.3 30 30 60 
 R 5’-TACGCACCACTTCTTCCATCACC-3’      
TP  F 5’-AATGTCATCCAGAGCCCAGAGCA-3’  0.5 30 30 60 
 R 5-GAACTTAACGTCCACCACCAGAG-3’      
TS F 5’-TTTACCTGAATCACATCGAGCCAC-3’  0.5 30 30 20 
 R 5’-GACTGACAATATCCTTCAAGCTCC-3’      
DPD F 5’-GGTCTTCAGTTTCTCCATAGTGGT-3’  0.5 20 20 45 
 R 5’-GACTCTGTCCATCCCAGTCTTGT-3’      
 
Table 4. Forward (F) and reverse (R) primers for real-time PCR:  Reaction 
conditions were 50°C for 2 min, 95°C for 10 min, followed by 40 cycles PCR with the 
temperature and times listed in the table. 
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Gene Vector Insert size 
(bp) 
Vector size 
(bp) 
Total size 
(bp) 
CES2 pVL1392 1680 9639 11319 
CES1 pCR Blunt TOPO II 1707 3519 5226 
TOPO I pCR4-TOPO 208 3957 4165 
β-GUS pCR Blunt TOPO II 264 3519 3783 
TP pCR Blunt TOPO II 216 3519 3735 
TS pCR Blunt TOPO II 209 3519 3728 
DPD pCR Blunt TOPO II 157 3519 3676 
 
Table 5. Plasmids used for standard curves in real-time PCR:  Reported insert 
size corresponds to PCR product size except in the cases of CES2 and CES1.  
Expected product size for CES2 and CES1 are 0.15 kb and 0.19 kb, respectively.  
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UGT1A1 sequencing  
An approximately 255 bp region surrounding the promoter region of the UGT1A1 
gene was amplified by PCR.  As per Monaghan et al. (1996), the forward primer was 5’-
AAGTGAACTCCCTGCTACCTT-3’and the reverse primer was 5’-CCACTGGGATCA 
ACAGTATCT -3’.  Five hundred ng of genomic DNA from either a normal biopsy or 
surgery sample were used as the template in a 50 μl PCR reaction.  The reactions 
contained 1x buffer, 1.75mM MgCl2, 0.8mM of each deoxynucleotide triphosphate, 0.25 
μM of each primer, and 0.05U/ μL AmpliTaq Gold (Applied Biosystems).  The PCR 
conditions were 95°C for 10 minutes followed by 30 cycles of 95°C for 30 s, 58°C for 40 
s, and 72°C for 40 s (Monaghan et al., 1996).  The PCR products were purified by 
electrophoresis on 2% agarose (Sigma) gels followed by extraction using the QIAquick 
Gel Extraction Kit.  The purified products were sequenced using the forward primer, and 
the chromatograms were analyzed for TA repeats in the TATA box region of the 
promoter. 
Clinical data and statistical analysis 
All clinical data were collected by members of the HOG GI03-53 team.  Clinical 
endpoints included tumor response and toxicity.  Correlation analysis of gene expression 
with clinical outcome was completed by statisticians involved with the HOG GI03-53 
project.  The data were considered significant if p < 0.05.  
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RESULTS 
I. Tissue-specific expression of CES2 splice variants  
Northern analysis 
 A multi-tissue northern blot was probed with cDNA specific for CES2+64 and 
CES2∆1-93 (Figure 9).  Wu et al. (2003) previously analyzed the blot for expression of 
CES2.  The CES2+64 sequence was identified in the 4.1 kb and 2.8 kb transcripts.  A < 1.7 
kb transcript was also present in the liver and heart. The CES2∆1-93 sequence was 
localized to the approximately 4 kb transcript.   
 
Figure 9. Northern analysis of CES2Δ1-93 and CES2+64 
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II. Analysis of CES2 and CES2∆458-473 in paired tumor and normal colon samples 
Expression of CES2 and CES2Δ458-473 in human colon samples  
Real-time PCR was used to quantify the expression levels of the CES2 and 
CES2Δ458-473 transcripts in 10 paired tumor and normal colon samples.  Forward primers 
(shown in bold in Figure 10) were designed to be variant-specific for CES2 and  
CES2Δ458-473.  Analysis of RNA quality by agarose gel electrophoresis showed little to no 
degradation.  Standard curves were created for both variants using DNA clones in the 
pVL1392 vector which were constructed by our laboratory.  Amplification of each 
standard curve was linear over a 100,000-fold range (r2=0.99) with respect to copy 
number (Figure 11).  The amplification efficiency, as calculated by the eppendorf real-
time PCR software, was ≥ 0.9 for each of the variants.  The uniformity of the PCR 
products was determined using melting curve analysis (Figure 12).  All cDNA samples 
were analyzed in triplicate with the standard deviation generally < 12 % for both CES2 
and CES2Δ458-473.   
The reproducibility of all the steps involved in real-time PCR was studied in 
control experiments.  In one experiment, RNA was isolated from five different pieces of 
the same tumor sample.  It was determined that < 1.6-fold variation in the CES2 copy 
number could be attributed to the entire method from tissue disruption through real-time 
PCR (Figure 13A).  In another experiment, one sample RNA was reverse transcribed in 
quintuplicate.  It was determined that < 1.3-fold variation in copy number could be 
attributed to reverse transcription (Figure 13B).  
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Figure 10. Alternative splicing in exon 10:  Alternative splicing in exon 10: (A) 
shows a partial DNA sequence for CES2 gene.  The exon 10 sequence is shaded.  
Alternative use of 5’ splice site in exon 10 results in CES2Δ458-473 variant which has 
a 48 bp deletion (boxed) in comparison to CES2. Variant specific-primer sequences 
are shown in bold. (B) The 16 amino acid deletion immediately following the active 
site H457 (bold) in the CES2Δ458-473 protein results from the 48 bp deletion in its 
transcript shown in Panel A. Unique peptides that were identified for CES2 and 
CES2Δ458-473 by LC-MS/MS are underlined (Schiel et al., 2007). 
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Figure 11. Real-time PCR standard curve for CES2Δ458-473:  The standard curve 
for CES2Δ458-473 was linear over a 100,000-fold range (r2=0.998).  The efficiency of 
the PCR was 1.00.  (The x-axis and y-axis are copy number and cycle number, 
respectively.) 
 
 
Figure 12. Melt curve analysis for CES2Δ458-473real-time PCR products:  All real-
time PCR products for CES2Δ458-473 had an average melting temperature of 83.90C 
indicating a single uniform product.  The three lines with no peaks represent the no 
template control samples.  (The x-axis and y-axis are temperature in C° and –dl/dT 
(%), respectively.) 
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Figure 13. Reproducibility of real-time PCR methods:  The reproducibility 
of all the steps involved in real-time PCR was analyzed.  (A) RNA from 
sample 1 was reverse transcribed in quintuplicate.  Less than a 1.3-fold 
variation in copy number was attributed to reverse transcription alone.  (B) 
RNA was isolated from five different pieces (1-5) of the same esophageal 
tumor sample.  A <1.6-fold variation in the CES2 copy numbers was 
attributed to the entire method from tissue disruption through real-time PCR.  
(C) Statistical summary of panels (A) and (B).   
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CES2 and CES2Δ458-473 transcripts were found in all tumor and normal colon 
samples.  There was a 45-fold variation in expression of CES2 transcript in normal tissue 
and a 27-fold variation in tumor tissue.  Among four of the paired samples, CES2 was 
expressed in greater abundance in tumor as compared to normal tissue (Figure 14A).  No 
significant linear correlation (R2=0.025) was found in CES2 transcript expression 
between the paired tumor and normal tissue samples. CES2Δ458-473 varied by 34-fold in 
normal tissue and 25-fold in the tumor tissues.  The percentage of CES2Δ458-473 transcript 
in colon tissue accounts for approximately 6% (SD < 1.3%) of the total CES2 transcripts 
(Figure 14B).   
Carboxylesterase activity in colon tissue lysates 
 The carboxylesterase activities of the colon tissue lysates were quantified using 
the 4-methylumbelliferyl acetate hydrolysis (4-MUA) assay and band densitometry 
analysis as described in the methods.  All samples showed non-specific carboxylesterase 
activity with 4-MUA as substrate (Table 6).  The range for normal samples was 2.5 to 9.8 
µmol mg-1 h-1 with a 4-fold variation, while the range for the tumor samples was 2.0-7.4 
µmol mg-1 h-1 with a 3.7-fold variation.  Non-denaturing PAGE was used to separate the 
carboxylesterases in the samples and purified CES2 protein was loaded on each gel as a 
control. The gel for paired colon tissue samples 5 through 7 is shown in Figure 15.  The 
band density attributable to CES2 was determined for each sample.  All samples 
demonstrated activity for 4-MUA in the non-denaturing PAGE assay (Table 6).  There 
was a 24-fold variation in normalized band density among the normal colon samples and 
an 8-fold variation among the tumor samples.   
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Figure 14. Expression of CES2 and CES2Δ458-473 in 10 paired tumor and normal 
colon samples:  (A) Real-time PCR was used to determine the amount of CES2 
transcripts in 10 paired tumor and normal colon samples (Methods III).  A 45-fold 
variation in expression of CES2 was found among the normal samples, and a 27-fold 
variation was found for the tumor samples.  There was no disease-specific expression 
pattern.  (B) CES2Δ458-473 was expressed in all of the colon tissues samples.  CES2Δ458-
473 accounts for ~6% of total CES2 transcript in all of the colon samples (Schiel et al., 
2007). 
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Figure 15. Non-denaturing polyacrylamide activy gel for paired colon tissue 
samples:  Colon tissue lysates from paired normal (N) and tumor (T) tissue, as well as 
control samples of CES1 and CES2, were electrophoresed on a non-denaturing gel.  The 
gel was incubated with 4-MUA and the product 4-MU was detected under UV light.  
Band densinometry analysis was completed and reported in Table 6.  The middle band 
has been previously observed but is not yet identified. 
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sample 4-MUA activity band density sample 4-MUA activity band density
N1 7.1 0.64 T1 5.8 0.65 
N2 6.6 0.74 T2 3.1 0.12 
N3 4.1 0.31 T3 5.5 0.51 
N4 8.0 0.78 T4 7.4 0.71 
N5 3.8 0.32 T5 7.2 0.57 
N6 9.8 0.55 T6 3.2 0.14 
N7 6.2 0.44 T7 2.0 0.09 
N8 2.5 0.03 T8 7.4 0.53 
N9 8.6 0.50 T9 2.2 0.12 
N10 6.7 0.44 T10 4.4 0.33 
Ave 6.3 0.48 Ave 4.8 0.38 
SD 2.2 0.22 SD 2.1 0.24 
 
Table 6. Expression and activity data for paired tumor (T) and normal (N) 
colon tissue samples:  Ten microliters of colon tissue lysate were incubated with 
0.5 mM 4-MUA in 90 mM potassium phosphate containing 40 mM potassium 
chloride buffer (pH 7.4) at 37°C.  Specific activity for 4-MUA was calculated in 
µmol mg-1 h-1.   CES2 band density was determined by running 50-100 µg of 
colon tissues lysates on non-denaturing PAGE.  The gels were exposed to 1 mM 
4-MUA in 100 mM potassium phosphate buffer (pH 6.0) for 10 minutes at room 
temperature.  Band density was measured by fluorescence.  Band densities were 
normalized to CES2 controls in order to account for variations between gels. 
Averages (Ave) and standard deviations (SD) are included (Schiel et al., 2007). 
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Statistical analysis 
 There was evidence of kurtosis (data not shown) for both the CES2 copy numbers 
(p-value=0.03) and band densities (p-value=0.04) of the tumor samples. Kurtosis is often 
an indication of bimodality (Darlington R.B., 2007). All other measurements in tumor 
and all measurements in normal tissue appeared to be normally distributed.  CES2 copy 
numbers, determined by real-time PCR, were subjected to linear regression analysis (JMP 
4.0) with 4-MUA hydrolase activity and normalized band density (Figure 16).  
Correlations of CES2 expression with 4-MUA hydrolase activity and band density are 
considered significant if p ≤ 0.05 (Takahashi et al., 2000).  CES2 copy numbers, in tumor 
samples, positively and significantly (p ≤ 0.0001) correlated with both 4-MUA hydrolase 
activity (r2 = 0.857) and band density (r2 = 0.982).  For the normal samples, CES2 copy 
numbers significantly correlated with 4-MUA hydrolase activity (p < 0.0436), but 
correlation with band density (p < 0.0546) was just outside the range of significance.  
Data from the normal and tumor samples were analyzed collectively, and significant 
correlation existed between CES2 copy numbers and both 4-MUA (p < 0.0001) and band 
density (p < 0.001). 
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Figure 16. Correlation of CES2 expression with carboxylesterase activty in 
colon tissue:  (A) Real-time PCR data for CES2 was subject to linear regression 
(JMP 4.0) with 4-MUA hydrolase activity (µmol mg-1 h-1) and normalized band 
density from corresponding samples.  The correlation coefficients and P values are 
reported.  Data are considered significant if p ≤ 0.05.  (B) Scatter plot showing 
significant, positive correlation between CES2 copy number and band density in 
tumor samples (Schiel et al., 2007). 
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III. Characterization of the CES2Δ458-473 variant   
 CES2 is a serine ester hydrolase (carboxylesterase) with Ser228, Glu345 and 
His457 forming its catalytic triad.  CES2 is the major carboxylesterase responsible for 
activation of CPT-11 (Khanna et al., 2000; Humerickhouse et al., 2000; Sanghani et al., 
2004).  A variant DNA sequence for CES2 was reported in the EST database.  This 
variant transcript has a 48 bp deletion (Figure 10A) that gives rise to a protein with a 
sixteen amino acid deletion immediately following the active site His457 residue (Figure 
10B).  Use of the SPIDEY software 
(http://www.ncbi.nlm.nih.gov/IEB/Research/Ostell/Spidey/index.html) to align the CES2 
(GI:37622884) and CES2Δ458-473 (GI:37622886) mRNA transcripts with the CES2 
genomic clone (GI:56788327) demonstrates that the exon 10 sequence contains good 5’ 
splice sites for both of the transcripts. Hence, the two transcripts are created by the use of 
alternate 5’ donor splice sites in exon 10.  This evidence is further supported by the 
identification of 14 EST sequences in the human EST database as determined by blasting 
the database with a 25-nucleotide sequence unique to CES2Δ458-473 (shown in bold in 
Figure 10).  
Expression and purification of the CES2Δ458-473 protein variant 
A partial EST clone for CES2Δ458-473 was obtained from ATCC (Image Clone ID 
6195662).  In the CES2Δ458-473 message, the final 48bp of exon 10 are removed by 
alternative splicing. The partial CES2Δ458-473 clone and CES2 in the pVL1392 vector were 
digested with Xba I and Sma I.  The CES2Δ458-473 Xba I/Sma I digestion fragment was 
ligated into the digested pVL139-CES2 vector introducing the 48 bp deletion.  Restriction 
digests and sequencing confirmed the selection of the correct clones.  A recombinant 
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baculovirus containing CES2Δ458-473 cDNA was used to express the recombinant 
CES2Δ458-473 protein in Sf9 insect cells.  CES2Δ458-473 was purified in a two-step protocol 
using concanavalin A (conA) affinity columns followed by preparative non-denaturing 
PAGE (Sun et al., 2004).  Due to its lack of 4-MUA hydrolase activity, during each 
purification step the protein elution profile of CES2Δ458-473 was compared with CES2 to 
identify the protein peak of interest.  The protein elution profile for CES2Δ458-473 was 
similar to CES2 for both purification steps. 
Analysis of the CES2Δ458-473 protein 
The purified CES2 and CES2Δ458-473 proteins were analyzed by SDS-PAGE 
(Figure 17A), western analysis (Figure 17B), non-denaturing polyacrylamide gel 
electrophoresis (Figure 17C and 5D), circular dichroism (CD) (Figure 17) and mass 
spectrometry to assess their identity, purity, and physical properties.  The calculated 
molecular weight of CES2Δ458-473 protein from the SDS-PAGE gel (Figure 17A) is 59 
kDa and the expected molecular weight is 57.3 kDa before glycosylation.  In the western 
blot analysis, both CES2 and CES2Δ458-473 were identified with an anti-CES2 antibody 
(Figure 17B).  Activity staining of the non-denaturing polyacrylamide gel showed that 
the CES2Δ458-473 protein lacks carboxylesterase activity for 4-MUA (Figure 17C).  
Coomassie blue stain of the same gel shows the protein in the CES2Δ458-473 lane (Lane 2, 
Figure 17D) migrating to the same place as CES2 (Lane 1, Figure 17D).  The identity of 
the recombinant CES2Δ458-473 protein was confirmed by mass spectrometry where   
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Figure 17. Characterizations of recombinant CES2Δ458-473 and CES2 
proteins:  Lane 1: Two µg of CES2 and Lane 2: Two µg of CES2Δ458-473 (A) 
SDS-PAGE stained with Coomassie blue (B) Western blot of the same gel using 
CES2 antibody (C) Non-denaturing PAGE stained for activity with 4-MUA (D) 
Non-denaturing PAGE from panel C stained for protein with Coomassie blue 
(E) CD spectrum of CES2 (E2) and CES2Δ458-473 (V2) performed under identical 
conditions (Schiel et al., 2007). 
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a tryptic peptide with one miscleavage, ADHVKFTEEEEQLSR, specific for CES2Δ458-473 
(underlined in Figure 17B) was identified.  Folding of CES2Δ458-473 protein was evaluated 
by circular dichroism.  The mean residue molar ellipticity was plotted as a function of 
wavelength (Figure 17E).  The secondary structure composition analysis was done with 
CDpro software. Results from the CONTIN/LL method showed that the compositions of 
CES2 and CES2Δ458-473 were 15 % α-helical, 34 % β-strand, 22 % turn, 29 % unordered 
and 20 % α-helix, 29 % β-strand, 22 % turn, 29 % unordered, respectively.   
CPT-11 hydrolase assay 
CES2Δ458-473 protein (0-50 μg) was incubated with 55 μM CPT-11 for 2 h to 
determine its CPT-11 hydrolase activity. Under these conditions, no significant SN-38  
(< 5 nM) peak was detected in any of the CES2Δ458-473 samples after 2 hours.  In 
comparison, 1.98 μM of SN-38 was detected when CES2 (30 μg) was incubated with the 
same concentration of CPT-11 for just 30 min (Figure 18).   
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Figure 18. CPT-11 hydrolysis by CES2 and CES2∆458-473:  Varying amounts of 
purified, recombinant CES2 and CES2Δ458-473 proteins were incubated with 55µM 
CPT-11. The reactions were carried out in 250 µl volume at 37°C. CES2 samples 
were incubated for 30 min and CES2Δ458-473 samples for 2h.  SN-38 formation was 
quantified by HPLC as described in material and methods.  (A) HPLC 
chromatograms are shown.  (B) SN-38 concentration was plotted as a function of 
protein concentration (Schiel et al., 2007).  
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IV. Characterization of the CES2+64 variant  
Cloning, expression, and purification of the CES2+64 variant 
The CES2+64 N-terminal coding sequence was amplified by PCR using human 
liver cDNA (BD Biosciences Clontech) as the template.  The forward primer introduced a 
Bgl II site immediately before the first ATG of CES2+64, and the PCR product included a 
natural Aar I site.  The 400 bp PCR product was purified and cloned into the pCR Blunt 
II-TOPO vector (Invitrogen).  The recombinant vector was transformed into TOP10 E. 
coli (Invitrogen).  Positively transformed colonies were selected for on LB plates with 
50μg/ml kanamycin. To amplify the recombinant vector, four colonies were cultured 
overnight.  Recombinant vectors were isolated by miniprep (Qiagen) and digested with 
EcoRI.  All digested clones yielded the expected 400 bp band on a 1% agarose gel.   
A recombinant CES2-pVL1392 vector had previously been constructed in our 
labarotory.  CES2 with a C-terminal His-tag was cloned into pVL1392 using an N-
terminal Bgl II site and a C-terminal Xba I site.  An Aar I restriction digest site is located 
108 bp downstream from the ATG start site of CES2.  To construct the full length 
CES2+64 coding sequence, the CES2-pVl1392 vector and the 400 bp product in the pCR 
Blunt II-TOPO vector were digested with Bgl II and Aar I.  A 300 bp fragment from the 
recombinant +64-pCR Blunt II-TOPO vector was gel purified and sub-cloned into the 
digested CES2-pVL1392 vector to form the recombinant CES2+64-pVL1392 vector.  The 
recombinant vector was transformed into TOP10 E. coli (Invitrogen), amplified, and was 
isolated by midiprep (Qiagen).  Sequencing, in both directions, confirmed the inclusion 
of the N-terminal coding sequence for CES2+64.      
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CES2+64 in the pVL1392 baculovirus transfer vector was co-tranfected with 
linearized baculogold viral DNA into Sf9insect cells to form recombinant CES2+64 virus.  
Plaque assays were completed to identify a virus of increase virulence.  Nine of the 
eleven analyzed plaques contained DNA encoding for CES2+64 (Figure 19).  The viral 
DNA that yielded the strongest PCR band on agarose gel electrophoresis was chosen for 
CES2+64 expression.  Sf9 cells were infected with the selected CES2+64 virus.  CES2+64 
was purified separately from both the media and the cells in a one-step procedure using 
nickel resin.  The CES2+64 protein in the media eluted from the nickel resin in the 60 mM 
imidazole and 100 mM imidazole fractions.  CES2+64protein purified from the cells was 
collected in the 60 mM imidazole fractions.  Fractions were pooled and concentrated 
resulting in 3 final samples 1) CES2+64media 60 , 2) CES2+64media 100, 3) CES2+64cells.  Eighty-
nine percent of the recovered activity appeared in the media and 61% was in the 60 mM 
imidazole fraction (Table 7).  The purification of the recombinant proteins was analyzed 
by SDS-PAGE (Figure 21 and Figure 22).  The protein purified from both the media and 
the cells have not been purified to homogeneity.  Table 7 details the protein 
concentration, specific activity and protein yield and activity for each of the three 
samples.  Three times more protein was purified from the media than from the cells.  
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Figure 19. PCR analysis of viral DNA for selection of a CES2+64virus:  
PCR was used to identify which P1 viral stock contained recombinant virus 
with CES2+64 DNA.  L=100 bp ladder.  The templates were ‘C’ DNA isolated 
from media of non-infected cells, ‘1-11’ = viral DNA representing the eleven 
P1 stocks, ‘+’ = CES2+64-pVL1392, ‘-’ = CES2-pVL1392, ntc = no template 
control.  All negative controls (C, -, and ntc) were clean.  The P1 stock from 
sample 8 was chosen for creating the P2 viral stock. 
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Sample  Concentration 
(mg/ml) 
Volume 
(ml) 
Total protein
(mg) 
Specific activity 
CES2+64 media 60 
 
1.12 2 2.2 51.5 
CES2+64 media 100 
 
1.04 1 1.0 52.6 
CES2+64 cells 60 
 
0.36 2.9 1.0 17.6 
 
Table 7. CES2+64 protein purification yield:  CES2+64 protein was purified separately 
from the media and cells of a 1 liter preparation of Sf9 insect cells.  The subscripts 
following CES2+64 indicate the sample from which the protein was purified (media or 
cells) and the concentration of imidazole (60 or 100mM) used to elute the protein from 
the nickel resin.  Protein concentrations were determined by the BioRad protein assay.  A 
total of 3.2 mg of protein was purified from the media as compared to 1 mg of protein 
purified from the cell pellet.  The specific activity and total activity are listed in µmol 
min-1 mg-1 and µmol min-1, respectively.    
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4-Methylumbelliferyl acetate hydrolysis assay  
The carboxylesterase activities of the purified CES2+64 samples were determined 
by the 4-MUA hydrolysis assay and protein concentration.  The average activities from 
CES2+64media 60 and CES2+64media 100 were 51.5 and 52.6 µmol min-1 mg-1, respectively.  
The 4-MUA hydrolysis activity of CES2+64cells was 17.6 µmol min-1 mg-1 (Table 7).    
Analytical non-denaturing polyacrylamide gel electrophoresis and western blot analysis 
 The CES2+64 samples and purified recombinant CES2 were electrophoresed on an 
8% non-denaturing polyacrylamide gel and stained for activity with 4-MUA (Figure 
22A).  The CES2+64media samples had only one activity band each.  The bands were 
similar in position and intensity to CES2.  The stains were not quantitative due to over-
saturation of the bands so recoveries in samples could not be compared from this data.  
CES2+64cells showed three distinct activity bands.  All three active bands of CES2+64cells 
and the active bands from both CES2+64media samples were identified by the CES2 
antibody (Figure 22B).  Several other bands lacking 4-MUA activity were also detected 
in the CES2+64 media and CES2 samples, especially in lanes 1 and 4 of Figure 22B.  The 
identity of these inactive bands is not known but they could be truncated or non-
glycosylated forms of CES2 or insect cell proteins.  CES2+64 samples were 
electrophoresed on a separate 8% non-denaturing polyacrylamide gel and stained for 
protein with Coomassie blue (Figure 23).  The protein banding pattern for the 
CES2+64media samples resembled that of CES2.  CES2+64cells migrates to the same vicinity 
as CES2; however, there were three distinct bands seen both by activity stain and western 
blotting.   
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Figure 22. Activity (A) and western blot (B) analysis of CES2+64:  Proteins 
were electrophoresed on an 8% non-denaturing gel and stained for activity.  The 
same gel was subsequently used for western blot analysis. Lane 1) 0.1 µg 
CES2+64media 60, Lane 2) 0.1 µg CES2+64media 100, Lane 3) 0.2 µg CES2+64cells 60, and 
Lane 4) 0.1 µg CES2. 
 
 
 
 
Figure 23. Coomassie blue staining of CES2+64 on a non-denaturing 
polyacrylamide gel:  Lanes 1) and 2) 2 µg and 5 µg CES2+64media 60, respectively; 
Lanes 3) and 4) 2 µg and 5 µg CES2+64media 100, respectively; Lanes 5) and 6) 2 µg 
and 5 µg CES2+64cells 60, respectively; and Lane 7) 2 µg CES2. 
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SDS-polyacrylamide gel electrophoresis and western blot analysis  
 The CES2+64purified proteins were electrophorsesed on an 8% polyacrylamide gel 
followed by either Coomassie blue staining or western analysis (Figure 24 and Figure 
25).  Based on sequence analysis, CES2+64 was predicted to be approximately 69 kDa.  
The CES2+64media samples migrated similarly to CES2 and were approximately 60 kDa.  
These bands were identified by the CES2 antibody.  Coomassie staining revealed that 
CES2+64cells was not purified to homogeneity, and there appeared to be two or three poorly 
separated bands that migrated similarly to CES2.  On western analysis, only one band 
was detected in the same position as CES2.  Western analysis identified several larger 
bands for CES2+64cells; however, these bands produced a weaker signal than the 60 kDa 
band.  
Glycosylation analysis of CES2+64   
 To determine whether CES2+64 was glycosylated, preliminary studies were 
completed to determine which lectin probe to use.  Digoxigenin-labeled- Galanthus 
nivalis agglutinin (GNA), Sambucus nigra agglutinin (SNA), and Datura stramonium 
agglutinin (DSA) were tested against CES2.  Only GNA, which binds to terminal 
mannose, produced a significant band for CES2 (data not shown).  CES2+64 samples and 
CES2 were analyzed for glycosylation following both SDS-PAGE and non-denaturing 
PAGE and subsequent transfer to PVDF membrane.  Following SDS-PAGE, all three 
CES2+64 samples appeared to be glycosylated (Figure 26A).  Because three discrete bands 
were detected by Coomassie and western for CES2+64cells under non-denaturing 
conditions, the glycosylation study was also completed for the non-denatured CES2+64 
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samples.  As expected CES2 and CES2+64media all had one glycosylated band.  The upper 
two bands of CES2+64cells were glycosylated, but the lower band was not (Figure 26B).  
 
  
 
 
Figure 24. SDS-PAGE analysis of recombinant CES2+64 proteins:  Purified 
recombinant proteins were electrophoresed on an 8% SDS-polyacrylamide gel 
and stained with Coomassie blue. L) Molecular weight markers; 1) 2 µg CES2; 
2) and 3) 5 µg and 10 µg CES2+64media 60, respectively; 4) and 5) 5 µg and 10 µg 
CES2+64media 100 , respectively; 6) and 7) 5 µg and ~9 µg CES2+64cells 60,  
respectively. 
 
 
 
Figure 25. Western blot analysis of recombinant CES2+64 proteins:  Purified 
recombinant proteins were electrophoresed on an 8% SDS-polyacrylamide gel 
and transferred to a membrane for western blot analysis with anti-CES2 
antibody.  1) and 2) 0.1 µg and 0.2 µg CES2+64cells 60,  respectively; 3) 0.1 µg 
CES2+64media 60; 4) 0.1 µg CES2+64media 100; 5) 0.1 µg CES2. 
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Figure 26. GNA glycosylation staining of recombinant CES2+64 proteins:  
CES2+64 samples and CES2 were electrophoresed by (A) SDS-PAGE: 1) CES2 2) 
CES2+64media 60, 3) CES2+64media 100, 4) CES2+64cells 100 and (B) non-denaturing PAGE 
1) CES2 2) CES2+64media 100, 3) CES2+64media 60, 4) CES2+64cells 100 followed by 
transfer to membranes.  Glycosylation was detected using the DIG Glycosylation kit 
(Roche).  All CES2 and CES2+64 bands were glycosylated except the third active 
band of CES2+64cells 100. 
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N-terminal sequencing 
 CES2+64media 60 was electrophoresed on by SDS-PAGE and CES2+64cells was 
electrophoresed by non-denaturing PAGE.  The proteins were transferred to PVDF 
membrane and stained with Coomassie blue.  The 60 kDa CES2+64media 60 band (#1) and 
the three CES2+64cells bands (#2, #3, #4) (Figure 27) were excised, treated with PGAP, 
and sent to Cambridge Peptides for N-terminal sequencing by Edman degradation.  
Although Coomassie staining indicated sufficient protein, Cambride Peptide reported that 
all samples were of “low intensity” indicating that protein recovery from the membrane 
for sequencing was poor.  All sequencing results are summarized in Table 8.  The first 
residue of bands #1, #2, and #3 were not successfully sequenced.  The sequence of 
residues 2-5, Ser-Ala-Ser-Pro, was the same for all four bands.  This sequence 
corresponded to the N-terminal of CES2 indicating that all CES2+64 bands were CES2 
and did not contain the additional 64 N-terminal residues. 
  
75 
  
 
 
Figure 27. PVDF membranes with CES2+64 protein bands for N-terminal 
sequencing:  (A) 11 μg CES2+64 purified from media (B) 57 μg of CES2+64 
purified from cells were electrophoresed by SDS-PAGE and non-denaturing 
PAGE, respectively.  Bands #1 through #4 were sent for N-terminal sequence 
analysis (see Table 8). 
 
 
N-terminal 
Residue Band #1 Band #2 Band #3 Band #4 
1 - - - - - - Q 
2 S S S S 
3 A A A A 
4 S S S S 
5 P P P P 
 
Table 8. N-terminal sequencing results for CES2+64:  The sequences were on 
the edge of detection for all four bands.  However, all sequences matched the N-
terminal sequence of CES2 indicating that the +64 region had been cleaved.  
Q=glutamine, S=serine, A=alanine, and P=proline 
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V. Sub-cellular localization of CES2 variants 
Three CES2-GFP clones were made to study their sub-cellular localization: 
pEGFP-CES2, pEGFP-CES2+64, and pEGFP-CES2∆1-93.  The N-terminal coding 
sequence of CES2+64 and CES2, including the signal sequence, and the entire coding 
region of CES2∆1-93 were amplified by PCR.  Each PCR product was flanked by a Bgl II 
and Sal I sites at the 5’ and 3’ ends, respectively.  A 5’- Sal I site and a 3’- HTEL coding 
sequence plus a Not I site were added by PCR to the EGFP sequence of pEGFP-N2.  The 
CES2 variant PCR products and the modified EGFP were each cloned into E. coli 
replication vectors and transformed in to E. coli.  Colonies were selected and grown in 
culture.  Recombinant vectors were isolated and digested with either Bgl II and Sal I or 
Sal I and Not I. The pEGFP-N2 vector was linearized with Bgl II and Sal I followed by 
dephosphorylation.  Recombinant CES2 variant-GFP constructs were made by ligation of 
the three pieces, CES2-variant, modified EGFP, and digested pEGFP-N2.  The 
recombinant CES2 variant-GFP constructs were transformed into E. coli.  Recombinant 
vectors were isolated by mini-prep from overnight cultures.  All constructs were 
confirmed by DNA sequencing.    
The recombinant CES2 variant-GFP constructs and the pEGFP-N2 vector alone 
were transfected into HCT-15 cells using the FuGene6 reagent (Roche).  The HCT-15 
cells had been seeded on poly-L-lysine coverslips.  An Axiovert 200 microscope (Zeiss) 
was used to visualize the localization of the chimeric GFP proteins over a 24 to 48-hour 
period.  CES2 and CES2+64 appeared to localize to the ER while CES2∆1-93 had a diffuse, 
cytosolic localization pattern (Figure 28) similar to GFP alone (not shown).   
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Figure 28. Localization of CES2 variant-GFP constructs in HCT-15 cells:  CES2 
and CES+64 were localized to the ER while CES2Δ1-93 remained in the cytoplasm. 
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VIII. The role of CES2, CES1, TOPO I, TP, TS, DPD, β-GUS, and UGT1A1 in the 
inter-individual variation in response to treatment of rectal cancer with irinotecan 
and capecitabine 
Expression of CES2, CES1, TOPO I, TP, TS, DPD, and β-GUS in paired tumor and 
normal rectal biopsy samples 
 
A protocol was successful developed to obtain high quality mRNA and DNA 
from small rectal biopsy samples (Figure 29).  Genomic DNA and mRNA were isolated 
from eleven paired tumor and normal biopsy samples using the Allprep DNA/RNA kit 
(Qiagen).  The mRNA and DNA quantity and to a degree quality, by the A260/280 ration, were 
analyzed using the ND-1000 Spectrophotometer (Nanodrop).  Standard curves were 
created for each gene from recombinant vectors constructed in our laboratory.  
Amplification of each standard curve was linear over a 100,000-fold range with respect to 
copy number (r2 > 0.99).  The amplification efficiency was ≥ 0.85 for each gene.  Melt 
curve analysis was used to determine the uniformity as the PCR products.  All cDNA 
samples were analyzed in triplicate, and the median expression is reported in Table 9. 
UGT1A1 sequencing  
 Genomic DNA, isolated from either a normal biopsy or surgery sample was used 
as a template in PCR to amplify the promoter region of UGT1A1.  PCR products were 
purified by agarose gel electrophoresis followed by extraction from the gel.  The purified 
products were sequenced, and the chromatograms were analyzed for TA insertions or 
deletions (Figure 30).  If the chromatogram appeared to contain two sequences, this 
indicated that the sample was heterozygous for the UGT1A1 promoter.  Four patient 
samples #4, #5, #6, and #8 were homozygous for (TA)6TAA/(TA)6TAA (6/6).  The other 
seven patient samples were heterozygous for the UGT1A1*28 allele, 
(TA)6TAA/(TA)7TAA (6/7).  
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Figure 29. Summary of the protocol for the HOG GI03-053 rectal tissue samples  
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Table 9. Gene expression data for HOG GI03-053 rectal samples:  Data are 
reported in copy numbers as determined by real-time PCR. 
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Figure 30. UGT1A1 sequencing chromatograms:  (A) Wild type, homozygous 
(TA)6TAA/ (TA)6TAA (6/6).  (B) Heterozygous for the UGT1A1*28 allele, 
(TA)6TAA/ (TA)7TAA (6/7). 
 
82 
Clinic data and statistical analysis 
 Clinical data were collected by members of the HOG GI03-53.  Statistical 
analysis was completed by statisticians in the HOG GI03-53 group.  In order to maintain 
objectivity during analysis of the tissue samples, we were not made aware of the clinical 
data for individual patients.  Patients were classified as exhibiting either a pathologic 
complete response (pCR) or a pathologic non-complete response (pNCR).  Four of the 
eleven patients had pCR while the remaining seven demonstrated pNCR.  Figure 31 
shows the rectal tumor gene expression profiles for all eleven patients grouped by pCR 
and pNCR.  The average expressions of individual genes were compared between pCR 
and pNCR (Figure 32).  A significantly higher CES2 expression was observed in the 
pNCR group (p=0.0291).  There was a trend towards higher expression of CES1, 
thymidine phosphorylase (TP), and thymidylate synthase (TS) in the pCR group.  No 
correlation has been observed between gene expression and toxicity profiles.  The 
collection of clinical data and gene expression data is on-going.   
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Figure 32. Comparison between complete responders (pCR) and non- complete 
responders (pNCR) with respect to the expression of TP, TS, TOPO I, and CES1 
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DISCUSSION  
 Carboxylesterases are responsible for the metabolism of numerous endogenous 
and xenobiotic compounds.  Irinotecan and capecitabine are two chemotherapy pro-drugs 
hydrolyzed by carboxylesterases.  Carboxylesterases convert the pro-drug irinotecan to 
its active form SN-38, which is 1000-fold more cytotoxic.  CES2, located predominately 
in the liver and intestines, is the most important enzyme for this activation 
(Humerickhouse, et al., 2000; Sanghani, et al., 2004).  Irinotecan has shown to be 
ineffective therapy for lymphomas and gallbladder tumors which lack CES2 expression 
suggesting that local expression of CES2 in tumors may influence treatment outcome (Xu 
et al., 2002).  High inter-individual variability in outcome has been demonstrated when 
irinotecan is used in the treatment of colorectal cancer.  One of the most debilitating 
adverse effects, delayed onset diarrhea has limited the use of irinotecan in some patients.  
Khanna et al. (2000) suggested that gut toxicity may be due to local conversion of 
irinotecan to SN-38 in the gastrointestinal mucosa.  Sanghani et al. (2003) reported 
significant variation of CES2 expression in 24 colon tumor samples.  We hypothesized 
that the levels of carboxylesterase in the tumor and surrounding normal tissue may 
contribute to the inter-individual variation in both response and adverse affects.   
The human genome is known to contain fewer than 30,000 genes yet over 90,000 
proteins are estimated to comprise the human proteome (Ast, 2004; Xing, 2007).  Single 
nucleotide polymorphisms (SNPs), alternative splicing and copy number variants (CNVs) 
all contribute to the formation of the complex human proteome.  Several CES2 SNPs 
have been studied; however, there is no consensus on their affect on CES2 expression 
and activity.  The Database of Genomic Variants (Zhang et al., 2006) does not report any 
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CNV for CES2, unlike CES1 which has a reported six CNVs.  Based on the EST 
database, we identified alternative splicing in exon 1 and exon 10 of CES2 (Figure 3).  
Two potential translation start sites were also noted in exon 1.  We proposed that splice 
variants of CES2 could contribute to the inter-individual variation in CES2 expression, 
activity, and ultimately therapeutic response to irinotecan and capecitabine.  We aimed to 
characterize the expression patterns and activities of several CES2 splice variants, 
CES2Δ458-473, CES2+64, and CES2Δ1-93.  CES2 is only one of several enzymes that 
contribute to the metabolism of irinotecan and capecitabine.  We designed a protocol to 
study the expression of CES2 and other genes involved with irinotecan and capecitabine 
metabolism with the ultimate goal of being able to tailor chemotherapy for individual 
patients.  
I. Characterization of CES2 splice variants 
Multi-tissue northern analysis revealed that CES2 is primarily expressed in the 
liver and gastrointestinal tract.  Expression has also been demonstrated in the heart, 
kidney, testis, and brain (Satoh et al., 2002).  There are three transcripts of approximately 
4 kb, 3 kb, and 2 kb in size found in various tissues (Satoh et al., 2002; Wu et al., 2003).  
There is discrepancy as to whether CES2 is expressed in skeletal muscle tissue (Satoh et 
al., 2002; Wu et al., 2003).  Wu et al. (2003) reported that different promoters explained 
the three CES2 transcripts on northern blot.  We proposed that alternative splicing 
contributes to the multiplicity of the mRNA transcripts.  A northern blot was probed for 
CES2∆1-93 and CES2+64 to determine if alternative splicing contributed to the multiple 
transcripts (Figure 9).  The sequence for CES2∆1-93 was found only in the 4.1 kb 
transcript.  Expression of the CES2+64 sequence was found in both the 4.1 kb and 2.8 kb 
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transcripts as well as a 1.7 kb transcript in the liver and heart.  These data suggest that 
CES2 is spliced in a tissue specific manner.  Trans-acting splice factors present in the 
different tissue are expected to contribute to the tissue-specific variation.  The AceView 
database currently reports eleven splice variants of CES2 (Thierry-Mieg and Thierry-
Mieg, 2006).  Variants are designated by a lowercase letter, in decreasing order of protein 
size, followed by the current release Apr07.  The sizes of several reported variants 
correspond with the different sized CES2 transcripts revealed by northern analysis.  The 
mRNA for variant aApr07is 4177 bp long and is in concordance with the identification of 
the CES2+64 sequence in the 4.1 kb transcript.  Variant bApr07,3901 bp, and variant 
cApr07, 4140 bp, may also contribute to the 4.1 kb transcript visualized by northern 
analysis.  Variant dApr07 yields a protein with a 93 amino acid deletion at the N-
terminus; however, the reported mRNA is 1970 bp.  The CES2∆1-93 sequence was 
identified in the 4.1 kb transcript, but a 1.9 kb transcript was not visualized by northern.  
The 1.9 kb mRNA may be expressed in very low abundance interfering with detection by 
northern.  Analysis of Aceview transcripts shows that only transcript aApr07 4177 bp 
would be responsible for formation of full-length protein.  In our original northern 
analysis (Satoh et al., 2002), a cDNA probe encompassing exons 7-10 identified only two 
transcripts of approximately 2 kb and 3 kb in the liver.  A 4 kb band was not detected in 
the liver, a site of high CES2 expression.  Therefore, AceView is an important tool for 
identifying multiple transcripts, but it is by no means exhaustive at this stage.  The 
complexity surrounding alternate transcripts increases if alternative splicing events are 
combined.  Further complicating the picture are the possible combinations of alternative 
splice variants and multiple promoters.  Additional northern analysis should be performed 
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with probes specific to the newly reported splice variants to better define CES2 
expression.  Understanding which CES2 splice variants are expressed in different tissues 
will allow researchers to focus their studies of CES2 in those tissues.  The 
pharmacokinetics of compounds metabolized by CES2 can be better understood by 
knowing which splice variants are expressed in a specific tissue.  
Expression and Activity of CES2 and CES2Δ458-473  
CES2 is the most widely studied of the CES2 splice variants.  The translated form 
of CES2 has 559 amino acids with a 26 amino acid leader sequence.  The active, 
glycosylated, microsomal form of CES2 has 533 amino acids.  Insertions or deletions 
created from splice variants are described as Δx-y relative to the translated 559 amino acid 
protein.   
Analysis of CES2 transcripts in the EST database reveals that combinations of 
alternate ATG start sites and 2 splicing events in exon 1 and exon 10 could lead to 6 
potential proteins (Figure 3).  A twenty-five nucleotide sequence (shown in bold in 
Figure 10) unique to the CES2Δ458-473 transcript was identified in 14 ESTs.  The transcript 
is missing the final 48 nucleotides from exon 10, and the resulting protein CES2Δ458-473 
lacks the 16 amino acid residues directly following the active site histidine.  The 
proximity of the deleted amino acids to the active site suggested that CES2Δ458-473 may 
differ in activity from CES2.   
The expression levels of the CES2Δ458-473 and CES2 transcripts were analyzed in 
tumor and normal colon tissue pairs using variant specific primers and real-time PCR.  
Primers were able to distinguish between alternate splicing events in exon 10 but could 
not detect any splicing events occurring in exon 1.  Thus copy numbers for CES2Δ458-473 
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and CES2 represented the total transcript levels differentiating only between normal and 
alternate splicing in exon 10, without regard for alternative splicing in exon 1.  Both the 
CES2Δ458-473 and CES2 variants were present in all 20 tissue samples, and CES2Δ458-473 
accounted for approximately 6% (SD < 1.3%) of the total CES2 transcript, suggesting 
that it was being spliced at a constant rate.  There was large inter-individual variation in 
CES2 expression among the tumor tissue samples and the normal colon samples, 27-fold 
and 45-fold respectively.  There was no significant difference in CES2 expression 
between tumor and normal colon samples which supports the findings of our previous 
report (Sanghani et al., 2003).  In six paired samples, CES2 expression was greater in the 
normal tissues, while the other four pairs have higher expression in tumor.  This 
variability suggests that inter-individual variation in expression of CES2 could account 
for differences in patient response to irinotecan therapy.  CES2 expression levels, 
especially in tumor tissue, may dictate whether or not irinotecan therapy is successful 
while CES2 expression levels in normal tissue may contribute to the severity of 
deleterious side-effects.   
For all real-time PCR studies copies numbers were determined using standard 
curves made from plasmids.  There is an on-going discussion as to whether the use of 
housekeeping genes is appropriate for normalization.  An ideal housekeeping gene is 
expressed at constant levels between tissues.  It can therefore be used as an internal 
control to account for errors introduced by the methods used in the quantification process.  
Studies have shown that even housekeeping genes have a variable range of expression 
especially between tissues types and between cancerous and normal tissues (Dheda et al., 
2004; Rubie et al., 2005).  We chose to report absolute copy numbers without 
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normalization to GAPDH or β-actin.  In order to verify the accuracy and precision of the 
reported copy numbers two reproducibility control experiments were performed.  RNA 
was isolated from five different pieces of the same tumor sample.  Less than 1.6-fold 
variation in the CES2 copy numbers could be attributed to the entire method from tissue 
disruption through real-time PCR (Figure 13).  A second experiment was completed in 
which one sample RNA was reverse transcribed in quintuplicate.  Less than a 1.3-fold 
variation in copy number was attributable to reverse transcription alone (Figure 13B).  
Accordingly we report absolute copy number in this study because the use of a 
housekeeping gene in these experiments would unduly increase the reported inter-
individual variation. 
CES2 expression data were subjected to linear regression analysis with two 
different measures of carboxylesterase activity, 4-MUA hydrolysis in vitro and band 
density of CES2 on nondenaturing PAGE with 4-MUA staining.  Unlike the previous 
study (Sanghani et. al. 2003), variant-specific primers were used to quantify the transcript 
for CES2 separately from the transcript for CES2Δ458-473.  CES2 expression in the colon 
tumor samples had significant positive correlation with 4-MUA hydrolase activity and 
band density.  These findings are in concordance with the data previously published by 
Sanghani et al. (2003) although the correlation coefficients are increased.  These 
increased correlations may be attributable to the use of variant specific primers as well as 
improved methods. CES2 expression in normal tissue was also found to have significant, 
positive correlation with 4-MUA hydrolase activity and positive correlation with band 
density (p ≤ 0.055).  Correlation values between expression and activity for the tumor 
samples were greater than the corresponding correlation values in normal samples.  It is 
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possible that the tumor samples are more homogenous in cell type than the normal 
samples, which may include muscular tissue in addition to mucosal tissue.  
Microdissection of tissue samples could be employed to obtain a more accuarate 
representation of CES2 expression in each tissue. 
If inter-individual variation in response to irinotecan treatment may be explained 
by variations in CES2 expression, it is important to examine the expression and activities 
of the CES2Δ458-473 variant and other splice variants.  CES2Δ458-473 was cloned and 
expressed to characterize its activity and physical properties.  When purifying the 
CES2Δ458-473 variant protein, the protein elution profile of CES2 was used as a guide.  The 
CES2Δ458-473 protein had an elution profile identical to CES2 for purification on 
concanavalin A and preparative non-denaturing PAGE.  Binding of the CES2Δ458-473 
protein to concanavalin A resin indicated that it is glycosylated.  CES2 and CES2Δ458-473 
proteins migrated similarly on non-denaturing PAGE (Figure 17D).  When incubated 
with 4-MUA, a substrate for which CES2 has high activity with a reported Kcat/Km value 
of 60,000 mM-1 min-1 (Pindel et al., 1997), CES2Δ458-473 demonstrated no activity.   
The lack of esterase activity demonstrated by the CES2Δ458-473 protein raised questions 
regarding its folding.  The circular dichroism (CD) spectrum for CES2Δ458-473 (Figure 
17E) shows the presence of a secondary structure similar to that of CES2.  The small 
increase in α-helical content and small decrease in β-strand content of CES2Δ458-473 in 
comparison to CES2 could be expected from the 16 amino acid deletion.  Although the 
CES2Δ458-473 protein lacked 4-MUA hydrolase activity, it was feasible that it retained 
activity for other substrates. The CPT-11 hydrolase activity of the CES2Δ458-473 protein 
was evaluated.  Even at highest concentration of CES2Δ458-473 protein, no significant 
92 
amount of SN-38 (< 5nM) was detected.  Based on these results we concluded that the 
CES2Δ458-473 protein lacked irinotecan hydrolase activity.  To date efforts to identify the 
CES2Δ458-473 protein in tissue samples have been unsuccessful because there is currently 
no antibody specific for the protein sequence flanking the deleted 16 amino acids of 
CES2Δ458-473.  CES2Δ458-473 varies by only 16 amino acids from CES2, so these two 
variants have not been distinguishable on SDS-PAGE. 
Characterization of CES2+64 
 There are two in-frame ATGs in exon1 of CES2.  If translation began at the first 
ATG, 64 amino acids would be added to the protein at the N-terminus.  We hypothesized 
that these additional amino acids would affect the activity of the protein as well its 
subcellular localization.  Analysis of CES2+64 by SignalP 3.0 software 
(http://www.cbs.dtu.dk/services/SignalP/) (Bendtsen et al., 2004; Nielsen et al., 1997) 
predicted no signal sequence in CES2+64.  Without a signal sequence, CES2+64 should not 
be targeted to the ER and should be expected to remain in the cytoplasm as an 
unglycosylated protein. 
The baculovirus system (BD Biosciences Pharmingen) (Sanghani et al., 2004; Sun 
et al., 2004) was used to express recombinant CES2+64.  The C-terminal ER retention 
sequence in CES2+64 was replaced with a His-tag at its C-terminus to simplify 
purification.  When using the baculovirus system, C-terminally His-tagged recombinant 
CES2 protein is secreted into the media.  Since we predicted CES2+64 to be a cytosolic 
protein, recombinant CES2+64 protein was purified purification from both the cells and 
the media.  A one-step procedure using nickel affinity chromatography resin was utilized 
for purification taking advantage of the C-terminal His-tag.  From the media, the elution 
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profile showed two protein peaks at 60mM and 100mM imidazole, CES2+64media 60 and 
CES2+64media 100, respectively.  CES2 predominantly elutes at 60 mM imidazole with 60% 
of the recovered protein in this fraction (Table 7).  Both peaks were collected and 
analyzed separately.  Another protein peak was eluted and represented only 11% of the 
recovered protein (Table 7).  Even after the purification process, the CES2+64cell was not a 
homogenous sample (Figure 21).  
Activity was studied using the 4-MUA hydrolysis assay.  CES2+64media 60 and 
CES2+64media 100 had similar specific activities, 51.5 and 52.6 µmol min-1 mg-1, 
respectively.  The activity of CES2+64cell was lower at 17.6 µmol min-1 mg-1.  In contrast 
native CES2 purified from human liver has a specific activity of 120 µmol min-1 mg-1 
(Pindel et al., 1997).  The impurity of CES2+64samples could account for the lower 
specific activity of media protein versus purified CES2. 
The samples were analyzed by non-denaturing PAGE and SDS-PAGE, both 
followed by western blot analysis.  On non-denaturing PAGE, both CES2+64media samples 
demonstrated one active band similar to CES2.  The CES2+64cell sample revealed three 
active bands.  The active CES2+64media bands and all three CES2+64cell bands were 
recognized on western blot by an anti-CES2 antibody.  Western blot analysis also 
revealed several inactive bands in the CES2+64media samples.  While the identity of these 
inactive bands is unclear, they may represent polymers or different glycosylation states of 
the protein. It is unlikely that they are due to cross reactivity between the anti-CES2 
antibody and an insect cell proteins.  Nickel resin was used to purify the recombinant 
His-tagged CES2+64, and all insect cell proteins should have been eliminated because 
they did not contain the His-tag.  Sequence analysis of CES2+64 predicts a 69 kDa protein.  
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However, on SDS-PAGE, the CES2+64media samples migrated similarly to CES2, a 60 kDa 
protein.   
CES2 is a glycosylated ER-protein.  If the additional 64 amino acids of CES2+64 
prevent recognition of the signal peptide as predicted, the protein should not be targeted 
to the ER.  Without translocation to the ER, CES2+64 should not be a glycosylated 
protein.  Glycosylation analysis of CES2+64cell and both CES2+64media bands was 
performed.  All active bands were glycosylated except the third CES2+64cell band.  The 
CES2+64media and the three CES2+64cell bands were sent for sequencing by automated 
Edman degradation.  Senter et al. (2001) reported that CES2 is blocked at its N-terminal.  
When the N-terminus is blocked by pyroglutamic acid, edman degradation is inhibited.  
Before sequencing, the samples were treated with Pfu Pyroglutamate Aminopeptidase to 
unblock the N-terminus by removing any pyroglutamic acid residues.  Although the four 
samples were of low intensity making sequencing difficult, the sequences for all four 
samples corresponded to the N-terminal sequence of the mature wild-type CES2 protein.  
This indicated that all four samples of the recombinant CES2+64protein purified from 
insect cells did not contain the additional 64 N-terminal amino acids.   
There are two potential explanations for this observation: 1) the signal sequence 
was still identified despite the additional 64 amino acids at the N-terminal or 2) 
translation begins at the second ATG and the first ATG was bypassed.  We believe that 
initiation at the second ATG is unlikely because translation was under the control of the 
strong polyhedrin viral promoter in this expression vector.   
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Sub-cellular localization of CES2 variants 
Wild-type CES2 has an endoplasmic reticulum translocation signal peptide at its 
N-terminus and an ER retention signal sequence at its C-terminus.  Therefore, it is 
targeted to and retained in the ER where it undergoes glycosylation.  In CES2+64 the 
signal peptide is preceded by a 64 amino acid addition and the signal peptide cleavage 
site will be between amino acids 90-91.  It is widely believed that signal peptides are 
generally located within the first 70 amino acids of a protein.  Based on predictions by 
SignalP 3.0 software (Bendtsen et al., 2004; Nielsen et al., 1997), we did not expect a 
signal sequence to be recognized in CES2+64.  If no signal sequence is recognized in 
CES2+64, then it should not go to the ER or become glycosylated.  The CES2Δ1-93 variant 
does not possess the signal peptide nor was a different one predicted; and therefore, it 
also should not be targeted to the ER or undergo glycosylation.  We constructed chimeric 
CES2 variant-GFP constructs and transfected them into HCT-15 cells.  As expected, the 
chimeric CES2-GFP protein exhibited an ER localization pattern and chimeric  
CES2Δ1-93-GFP protein was localized in the cytoplasm.  Further research should be done 
on CES2Δ1-93.  The deletion of the first 93 amino acids may also significantly affect the 
structure and activity of the CES2Δ1-93 protein compared to CES2.  Similar to the chimeric 
CES2-GFP protein, the chimeric CES2+64-GFP protein also exhibited an ER localization 
pattern.  This suggests, as with the glycosylation experiment, that 1) the signal peptide is 
recognized or 2) translation begins at the second ATG.  If the signal peptide is 
recognized, SignalP 3.0 does not accurately predict the signal sequence for ER 
localization.   
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II. The role of CES2, CES1, TOPO I, TP, TS, DPD, β-GUS, and UGT1A1 in the 
inter-individual variation in response to treatment of rectal cancer with irinotecan 
and capecitabine 
 Capecitabine and irinotecan are pro-drugs used in the treatment of colorectal 
cancer.  Irinotecan is converted to SN-38, a potent topoisomerase I inhibitor, by 
carboxylesterases (Figure 4).  CES2 has a greater affinity for irinotecan and higher 
catalytic efficiency for irinotecan when compared with CES1.  Capecitabine is an oral 
pro-drug for 5-FU which has been the mainstay of colorectal chemotherapy for over the 
past 50 years.  Studies have shown that capecitabine can successfully replace 5-FU in 
dosing regimens.  The first step in the activation of capecitabine is mediated by 
carboxylesterases (Figure 5).  Both CES1 and CES2 have similar catalytic efficiency for 
capecitabine.  While carboxylesterases play a crucial role in the activation of both 
irinotecan and capecitabine, they are not the only enzymes that affect the metabolism of 
these pro-drugs.  
The active metabolite of irinotecan SN-38 is inactivated to SN-38G through 
glucuronidation that is mediated by UDP-glucuronosyltransferases (UGT), especially 
UGT1A1.  β-glucuronidase in both the tissue and the gut flora can convert the inactive 
SN-38G back to the active form SN-38 (Takasuna et al., 1996).  Enterohepatic 
recirculation is believed to play a role in the complexity of irinotecan metabolism.   
 After conversion of capecitabine to 5’-DFCR by carboxylesterases, cytidine 
deaminase, which is highly expressed in the liver and some solid tumors, converts 5’-
DFCR to 5’-DFUR (Miwa et al., 1998).  Thymidine phosphorylase converts 5’-DFUR to 
the active 5-FU.  Increased expression of  thymidine phosphorylase in many tumors 
guided the development of capecitabine as a pro-drug of 5-FU (Miwa et al., 1998).  
Elevated thymidine phosphorylase contributes to thymidine salvage as well as to 
97 
angiogenesis (Brown and Bicknell, 1998).  5-FU is incorporated into nucleotide 
metabolites that interfere with DNA and RNA synthesis.  FdUMP binds to thymidylate 
synthase and decreases the production of thymidine.  Dihydrophyrimidine dehydrogenase 
inactivates 5-FU.   
There is high inter-individual variation in response the therapy with both 
irinotecan and capecitabine.  Numerous studies have been completed to study how the 
different genes involved in the metabolism of these drugs contribute to therapeutic 
efficacy and adverse outcomes.  Our laboratory, along with others, have proposed that 
CES2 may contribute to variations in response to irinotecan (Sanghani et al., 2003; Xie et 
al., 2002; Xu et al., 2002).  Other groups have examined the effects of UGT1A on 
irinotecan treatment outcomes (Carlini et al., 2005; Gagne et al., 2002; Hanioka et al., 
2001; Innocenti et al., 2004; Jinno et al., 2003; Lankisch et al., 2005; Tukey et al., 2002).  
TA insertions into the TATA box region of UGT1A1 affect the promoter activity.  The 
UGT1A1*28 allele has an additional TA insertion (TA)7TAA and decreases the promoter 
activity by 70% (Ramchandani et al., 2007).  Patients who are homozygous for the 
UGT1A1*28 allele have demonstrated an increased risk for toxicity, especially 
neutropenia (McLeod and Watters, 2004; Rouits et al., 2004).  β-GUS expression has 
been correlated to irinotecan induced diarrhea. (Kehrer et al., 2000; Takasuna et al., 1996; 
Tobin et al., 2006).  Expression and activity of topoisomerase I, the target of irinotecan, 
were found to best predict response to irinotecan (Guichard et al., 1999; Jansen et al., 
1997; Pavillard et al., 2004; Sanghani et al., 2003).  When treated with 5-FU, colorectal 
cancer patients whose tumors expressed low levels of TS, TP, and DPD were found to 
have prolonged survival as compared to patients whose tumors had high expression of 
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any one of those genes (Salonga et al., 2000).  This study supported using more than one 
predictor of response to increase identification of patients who respond to therapy. 
A Hoosier Oncology Group HOG GI03-53 study was designed to evaluate the 
clinical and pathologic outcomes in rectal cancer patients treated with a combination of 
irinotecan, capecitabine, and radiation followed by surgery.  Biopsy samples were 
collected from normal and tumor tissue prior to the initiation of therapy.  Samples were 
also collected from tissues excised during surgery.  Clinic data including tumor response 
and adverse outcomes were amassed throughout the study.  A protocol was developed to 
study the expression of eight genes involved with the metabolism of irinotecan and 
capecitabine (Figure 29).  The design of this experiment studies five genes, potential 
predictors of response, found in metabolic pathway of each drug.  CES1, CES2, UGT1A1, 
β-GUS, and TOPO I are in the irinotecan pathway while CES1, CES2, TP, TS, and DPD 
contribute to the metabolism of capecitabine.  The goal of this study is to find 
correlations between the clinical data and gene expression in order to predict treatment 
outcomes and tailor chemotherapy for each patient. 
Real-time PCR experiments were designed to study the expression of CES2, 
CES1, TOPO I, TP, TS, DPD, and β-GUS.  Methods were designed to sequence the 
promoter region of UGT1A1.  We report protocol development and preliminary data from 
the biopsy samples of eleven patients.     
RNA and genomic DNA were isolated from the biopsy samples using 
QIAshredders and the Allprep DNA/RNA kit from Qiagen. RNA was quantified and 
reverse transcribed using previously described methods (Schiel et al., 2007).  For real-
time PCR analysis, standard curves with a 100,000-fold linear amplification range with 
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respect to copy number were designed for CES2, CES1, TOPO I, TP, TS, DPD, and β-
GUS.  Gene expression was reported in absolute copy numbers without normalization to 
a housekeeping gene (Schiel et al., 2007).  Data were collect on normal and tumor rectal 
tissue sample from eleven patients.  We fully expect this protocol to be translatable to 
studying the biopsy samples from newly accrued patients as well as corresponding 
surgery samples. 
The promoter area of UGT1A1 was amplified by PCR using primers and reaction 
conditions described by (Monaghan et al., 1996).  Genomic DNA from either normal 
biopsy or surgery samples was used as a template.  No research was found to suggest an 
increased rate of mutation in the UGT1A1 promoter in tumor tissue.  Therefore 
sequencing was only completed for normal rectal tissue samples.  However, genomic 
DNA was collected and stored at -70°C for both normal and tumor tissue for any desired 
future studies.  Purified PCR samples were sequenced by the DNA Sequencing Core 
Facility at Indiana University School of Medicine.  Chromatograms of each sample were 
inspected to determine homozygosity or heterozygosity as well as the number of TA 
repeats in the TATA box region.  The geneotype was determined for all eleven patient 
samples.   
Patient accrual and the gathering of clinical data and gene expression data are 
ongoing for the HOG GI03-53 study.  Preliminary results from the first eleven patients 
indicate that the capecitabine/irinotecan regimen is well tolerated.  Correlative studies 
between individual gene expression and therapy response, classified as pathologic 
complete response (pCR) or pathologic non-complete response (pNCR), suggest a trend 
for elevated TP, TS, and CES1 expression in pCR patients.  This is in contrast to studies 
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that indicate, tumors responding to 5-FU have low expression of DPD, TS, and TP 
(Metzger et al., 1998; Salonga et al., 2000); however, capecitabine requires TP for 
conversion to 5-FU which would support the trend for elevated TP in pCR patients.  
Recent studies with capecitabine have indicated that TP is predictive of response to 
capecitabine for breast and gastric cancers (Andreetta et al., 2008; Koizumi et al., 2008).  
Those studies did not include irinotecan in the therapy regimen.  Czejka et al. (2005) 
reported that capecitabine contributed to decreased formation of SN-38 after irinotecan 
infusion; however, irinotecan pharmacokinetics was not significantly affected.  Further 
statistical analysis will be performed as more clinical data and gene expression data is 
accrued.  The collection of both biopsy and surgery samples will provide an opportunity 
to study the effects of irinotecan and capecitabine on gene expression.  Kocakova et al. 
(2007) have found that chemoradiotherapy induces expression of TP and TS mRNA.  
Further studies could include the study of protein activity and its correlation with both 
gene expression and clinical response.  Studies of cellular transporters of irinotecan and 
its metabolites, which are also believed to contribute to the inter-individual response to 
therapy (de Jong et al., 2007; Mathijssen et al., 2001) could be considered.  
III. Summary 
 CES2 is an important enzyme for the activation of irinotecan and capecitabine, 
two pro-drugs used for the treatment of colorectal cancer.  There is high inter-individual 
variation in response to treatment with both irinotecan and capecitabine.  To characterize 
CES2 expression and activity as well as its role in the metabolism of irinotecan and 
capecitabine, basic and translational research was performed.  Through analysis of the 
EST database, two ATG translation start sites and splicing events in exon 1 and exon 10 
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were identified for CES2.  Three resulting protein variants CES2Δ458-473, CES2+64, and 
CES2Δ1-93 along with CES2 were studied with regards to expression patterns and enzyme 
activity.  Knowledge of the splice variants yielded insight into the CES2 expression 
pattern on northern analysis.  Significant variation in CES2 expression was found among 
10 pairs of tumor and normal colon tissue; however, no expression pattern difference was 
identified between tumor and normal sample pairs.  CES2Δ458-473, a variant missing 16 
amino acids after the activite site histidine, was determined to be inactive although it was 
expressed at approximately 6% in the 10 paired colon samples.  Extensive 
characterization of CES2+64 indicated that its mature protein product was in fact CES2 
suggesting that the native leader sequence is recognized in spite of the addition of 64 N-
terminal amino acids.  Sub-cellular localization studies showed that, unlike CES2 and 
CES2+64 which localize to the ER, CES2Δ1-93 is trafficked to the cytoplasm.  The methods 
employed in studying these variants can be used for characterizing newly discovered 
CES2 variants.  Real-time PCR methods that were developed for CES2 have been 
translated into the study of six additional genes contributing to the metabolism of 
irinotecan and capecitabine.  In collaboration with the Hoosier Oncology Group, we will 
continue to gather clinical and gene expression data from rectal cancer patients being 
treated with a combination of capecitabine and irinotecan.  The ultimate goal would be to 
tailor chemotherapy regimens to best fit the drug metabolic profile for each patient.  
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